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ABSTRACT 
Neural stem cells hold promise for future treatment of spinal cord injury. Various 
aspects regarding cell fate specification, manufacturing and monitoring, with 
implications for clinical applications of these cells, are discussed herein. Neural stem 
cells can be obtained from a number of sources, including fetal tissue and pluripotent 
embryonic stem cells. Transplantation of cells derived from immature sources is 
associated with tumor risk, which needs to be thoroughly investigated. We have shown 
that assessment of pluripotency should preferably be performed in the intended target 
compartment, as commonly used teratoma tests failed to detect pluripotent cells 
remaining after neural induction, cells that after transplantation gave rise to tumors in 
the central nervous system of model animals. We also found that among non-
pluripotent neural stem/progenitor cells (NPCs) from human fetal tissue, occasional 
cells expressed mRNA for genes associated with the pluripotent phenotype. The 
phenotype of these NPCs showed no overt differences from the others, but live-cell 
imaging showed that all NPCs constantly changed their morphology. Surprisingly, 
mRNA for pluripotency genes was not restricted to a certain subpopulation of cells. 
Rather, transcripts of these genes transiently appeared in most cells, but during short 
periods. In a similar way, we found that expression of markers such as PSA-NCAM 
and A2B5, associated with more differentiated phenotypes, entailed a propensity for 
differentiation, but not fate restriction. Isolated cell populations with either high or low 
immunoreactivity for CD133, CD15, CD24, CD29, PSA-NCAM or A2B5 both 
reconstructed the parental distribution of immunoreactivity after about two weeks in 
culture. Transcriptome analysis and in vitro studies confirmed that the reversible 
expression of markers was a reflection of reversible phenotypic identity. This finding 
requires that phenotype interconversion is added to the hierarchical model of neural fate 
determination in vitro. Furthermore, we have developed and evaluated a device for 
automatized mechanical dissociation of cell aggregates in culture, in compliance with 
regulatory guidelines for production of cells for transplantation, and shown its 
usefulness in long-term NPC cultures. 
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1 INTRODUCTION 
1.1 CLINICAL BACKGROUND 
1.1.1 Spinal Cord Injury (SCI) 
Traumatic injury to the spinal cord (SCI) causes loss of sensory and motor function as 
well as disruption of autonomic functions. The most common causes for SCI are traffic 
accidents and falling accidents, and often, young individuals are affected. Assessments 
of quality-of-life parameters for afflicted individuals indicate that medical problems 
such as neurogenic pain, pressure sores, spasticity, bladder dysfunction, bowel 
dysfunction and sexual dysfunction affect their well-being, often to a larger degree than 
the extent of their motor impairment, which is the disability that most people associate 
with SCI (Westgren and Levi, 1998). In addition, these patients face increased risk of 
cardiovascular complications and shorter life expectancy (Middleton et al., 2012). The 
reported global incidence of SCI - between 8 and 246 cases per million inhabitants per 
year - varies between regions. The variation is attributable to both socioeconomic and 
cultural factors as well as to differences in definition and survey methodology. Global 
reported prevalence varies from about 100 to 1,000 per million inhabitants. Prevalence 
is rising mainly due to increased survival of SCI patients (Furlan et al., 2013; Singh et 
al., 2014). 
 
1.1.2 Pathophysiology of SCI 
The progress of traumatic SCI is usually divided into three phases, acute, sub-
acute/secondary and chronic. In the acute phase, encompassing the immediate injury 
and the following days, mechanical damage immediately ruptures neural and vascular 
tissue, inducing cell necrosis and ischemia as well as neurogenic chock, which lasts for 
about 24 hours and represents a general failure of the neuronal network. The secondary 
phase overlaps the acute and includes excitotoxic insult induced by glutamate released 
by ruptured cells. Apoptosis, or programmed cell death, occurs as a result from excess 
glutamate signaling. Lipid peroxidation and release of free radicals further damage the 
tissue. Astrocyte activation and gliosis are accompanied by inflammatory immune 
responses by invading neutrophils and lymphocytes. In addition, factors inhibiting 
neurite growth are expressed at the lesion site, obstructing regenerative sprouting of 
axons. Finally, in the chronic phase, scar tissue is formed, and alterations in receptor 
and channel protein expression and behavior create a new environment, further 
exacerbating demyelination and apoptosis (Hulsebosch, 2002).  
 
Spontaneous recovery occurs in the period after traumatic spinal cord injury as the 
initial spinal chock abates over weeks or months (Ditunno et al., 2004) and some of the 
consequences of injury are compensated for by neuronal plasticity. Although the 
neurological symptoms may still improve a year after injury, there is in most cases very 
limited spontaneous recovery long term, and, historically, no treatments and certainly 
no cures have been available. In ancient Egypt, records were kept on spinal cord injured 
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patients, and somewhat laconically describing them as having “an ailment not to be 
treated”. The limited ability of the human spinal cord to heal itself after injury can most 
certainly be ascribed to the fact that there is limited favorable evolutionary pressure for 
such a capacity in a severely injured spinal cord. Rather, the regenerative compensatory 
plasticity that does exist, albeit restricted, has been shown to form aberrant neuronal 
circuits, leading to progressive neuronal dysfunction (Beauparlant et al., 2013). With 
the advent of modern medicine and improved hygiene, lethality following SCI has 
dropped dramatically and the hope for effective treatment and even cure is rising 
steadily. 
 
1.1.3 Therapies for SCI 
1.1.3.1 Rescue Strategies and Pharmacological Treatment 
Immediate intervention following injury is potentially important to restrict the 
secondary deleterious effects that include ischemia and inflammation at system level, 
and glutamate excitotoxicity and free radical-induced cell death at the molecular level. 
Strategies that routinely have been employed clinically include decompression surgery 
and high-dose infusion of corticosteroids, primarily methylprednisolone, which 
robustly ameliorates injury symptoms in rodent SCI models, and initially was claimed 
to lead to significant clinical improvement of neurological outcome (Bracken et al., 
1990). However, clinical use of methylprednisolone (A-Methapred, Solu-Medrol) has 
in recent years been advised against due to questionable beneficial effects in 
prospective blinded randomized trials, and adverse deleterious effects such as gastro-
intestinal bleeding, wound infections and hyperglycemia. Although the scientific data 
does not support the use of high-dose methylprednisolone after SCI, there is no 
absolute consensus among clinicians (Bracken, 2012; Cheung et al., 2015; Evaniew et 
al., 2016).  
Other strategies aiming for neuroprotection include cooling of the spinal cord, 
administration of tetracyclins and glutamate antagonists and hyperbaric oxygen 
treatment (Asamoto et al., 2000; Casha et al., 2012; Hansebout and Hansebout, 2014; 
Xu et al., 2004).  
Strategies to promote the regeneration of injured tissue after SCI strive to alter the 
microenvironment, which is generally non-permissive to growth. Cells in the intact and 
injured spinal cord express a variety of attractant and repulsive molecules such as 
netrins, integrins and matrix molecules including chondroitin sulfate proteoglycans 
(CSPGs). Several clinical strategies to inhibit CSPGs have been developed (Kim et al., 
2017). The most famous and well-studied neurite growth inhibitor is probably Nogo, a 
protein expressed in the central nervous system (CNS) known to inhibit axon 
regeneration. Blocking Nogo activity at its receptor or by sequestering it has been 
shown to protect and rescue neurons in animal injury models. However, it is likely that 
such an approach will have to be combined with other therapeutic strategies to 
maximize functional recovery after SCI (Schweigreiter and Bandtlow, 2006). 
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1.1.3.2 Cell Transplantation 
Several possible ways by which transplanted cells can contribute to the improvement of 
motor function after SCI have been conceived. The beneficial effects in SCI have been 
suggested to include neuroprotection, enhanced regenerative growth, 
immunomodulation, cell replacement and functional support. In most animal studies 
the time window of successful transplantation has been limited, and the biggest effect is 
seen when transplantation is performed in the acute or sub-acute stage of the injury. 
Several studies have showed that the mechanism behind the treatment effect is that the 
graft provides support for neurons-at-risk, possibly through the release of trophic 
factors. It has been claimed that acute transplantation is less effective than sub-acute 
because the inflammatory situation acutely after injury decreases graft survival, but 
results from our research group contradicted this statement (Emgard et al., 2014). With 
a delay of more than 1–2 weeks the time window for protective effects in rodents 
closes, but a window of opportunity to enhance regeneration remains for some time, 
until the subsequent formation of the glial scar impedes the effect of the transplant. The 
relation between post-injury time of transplantation and injury progression of rodent 
models eventually needs to be translated into the human setting. Different cell types are 
believed to exert different effects, and a few clinical trials have been initiated following 
different tracks, using fetal cells, oligodendrocyte progenitors, autologous Schwann 
cells, mesenchymal stromal cells or microglia (Assinck et al., 2017). 
 
Human fetal neural progenitor cells (hNPCs) from abortion material, similar to cells 
used in this thesis, have been used in the Pathway Study, conducted by the company 
StemCells Inc. Part of the study was randomized and single-blinded, designed to 
evaluate the efficacy of allogeneic transplantation of fetal brain-derived hNPCs to 12 
patients with thoracic, sub-acute SCI. The results of interim analysis revealed 
differences in motor strength that favored the treatment group, but the magnitude of 
the effect was lower than the company had hoped for, which led to termination of the 
study (see (Anderson et al., 2017a)), (clinicaltrials.gov). Preclinical data showed that 
mice and rats transplanted with the cells could recover sensory as well as motor 
function after SCI. Mechanisms thought to be responsible for functional recovery 
included neuroprotection, remyelination and synaptic integration (Tsukamoto et al., 
2013). However, a recent evaluation in rodent models of the specific cell lines used in 
the Pathway Study found no evidence of efficacy, raising questions about the validation 
of cells intended for clinical trials (Anderson et al., 2017a). 
 
The first study to use cells derived from human embryonic stem cells (hESCs) for 
treatment of SCI was conducted by the US-based company Geron Inc. Oligodendrocyte 
progenitors (OPCs) derived from hESCs were transplanted to five SCI patients, aiming 
primarily for re-myelinisation of host neurons. The study found no adverse effects, but 
was discontinued for financial reasons in 2011. The company Asterias Biotherapeutics 
used higher doses of the same cells in a phase 1 clinical trial that was completed in 
2014 without finding adverse effects. They are currently recruiting patients to a study 
investigating even higher doses. The hESC-derived OPC transplants have been shown 
to attenuate lesion pathogenesis and improve recovery of forelimb function in rat SCI 
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models (Sharp et al., 2010). Interestingly, for a short period Geron Inc. published in 
their web site information that the OPCs released several factors that could be 
protective, and that antibodies to TGFβ2 blocked the treatment effects in a study of 
the OPCs in SCI rats. This information was removed after a few weeks. 
 
The rationale behind cell transplantation of Schwann cells for SCI is to support 
regenerative axonal growth by myelinating sprouting host axons, to remyelinate axons 
that were demyelinated after the injury, as well as release of neurotrophic factors and 
extra-cellular matrix molecules. An Iranian study of 33 patients transplanted with 
autologous Schwann cells with a 2-year follow-up found no adverse effects and signs 
of improved sensory function (Saberi et al., 2011). The Miami Project to Cure Paralysis 
has also successfully completed a phase 1 study using autologous Schwann cells 
(Anderson et al., 2017b). 
 
Mesenchymal stem/stromal cells (MSCs) are comparatively simple to culture and can 
be harvested from various tissues in patients and used for autologous transplantation 
without immunosuppression. The effects of MSCs are mainly attributed to their anti-
inflammatory effects, but some studies suggested they could differentiate into 
neurons (Jiang et al., 2002). The latter hypothesis is however questioned by many 
researchers (Franco Lambert et al., 2009). Several safety studies in SCI patients have 
been conducted using MSCs, none of which have reported any concerns. However, 
functional effects, presumably resulting from neuroprotection, have been absent or 
very small (Dasari et al., 2014).  
 
All cell transplantation strategies require cells cultured in accordance with 
regulations, good manufacturing practices (GMP), stipulated by regulatory agencies. 
The basic principles of GMP include good hygiene, controlled and well-defined 
conditions, thorough documentation and traceability of compounds. Production of 
human cells for transplantation under GMP specifically demands minimal 
contribution of xenogeneic compounds in the culturing procedures, to avoid transfer 
of pathogens or other genetic material. This has expedited the production of feeder-
free conditions and defined media devoid of animal products for culturing of cells 
intended for transplantation, for instance. Splitting of cell cultures still relies on 
proteolytic enzymes that catalyze separation of cell aggregates by cutting cell 
adhesion molecules. We have developed and evaluated a mechanical device, called 
the Biogrid, described in paper IV, that dissociates cell aggregates without relying on 
the use of enzymes. 
 
1.1.3.3 Other Treatment Strategies 
The CNS is partly “immune privileged”, meaning that introduction of antigens from 
infection or trauma fail to elicit a proper inflammatory immune response. The blood-
brain barrier was widely believed to constitute an impenetrable wall separating the CNS 
from the systemic immune system until Michal Schwartz and co-workers discovered in 
the late 90ies that immune cells are pivotal for CNS neuroprotection and repair, 
although their spontaneous recruitment to the CNS is insufficient (Moalem et al., 
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1999). Treatment strategies involving modulation of immune response, including 
transplantation of activated macrophages, to resolve deleterious inflammatory 
responses following CNS injury are currently being developed, but the first clinical 
study, ProCord, conducted by the company ProNeuron, was closed prematurely due to 
a combination of funding problems and lack of obvious beneficial effects (Jones et al., 
2010). 
 
Recent rapid development in areas such as micro-robotics, biosensors and material 
research has made ideas about human/machine interactions increasingly realistic. 
Robot-assisted gait training (RAGT) has been used in rehabilitation since the late 90ies. 
Brain computer interfaces (BCIs) are devices that measure brain activity and translate 
it into control signals used for communication, environment control or upper 
extremity neuroprostheses in which Functional Electrical Stimulation (FES) uses 
surface electrodes to create purposeful contractions for improved motor function 
(Rupp, 2014). Importantly, the development of mechanical devices such as 
exoskeletons focuses on motor performance, and although increased mobility is linked 
to better cardiac function, bowel function and quality of life, many dysfunctions 
troubling SCI patients, such as urinary bladder problems, pain and spasticity, are not 
addressed. For complete restoration of spinal cord function, replacement of lost 
neuronal signaling is most likely necessary. In the future, combinations of beneficial 
therapies will likely be used, possibly using gene therapy or other ways to manipulate 
the microenvironment (Baptiste and Fehlings, 2006; Muheremu et al., 2016; Peng et al., 
2015; Sahni and Kessler, 2010; Zhao and Fawcett, 2013).  
 
The recent shut-down of three high-profile clinical trials (ProNeuron, StemCells Inc. 
and Geron) demonstrates the tremendous financial pressure that lies on companies 
performing stem cell-based clinical trials in SCI. As a matter of fact, StemCells Inc. has 
recently merged with the Israeli company Microbot Medical, which specializes in 
micro-robotic technologies. The failures also show there is a mismatch between the 
requirements of stem cell researchers and the expectations of investors (Smalley, 2016). 
And that stem cell science is hard. Really hard. 
 
1.2 CELLULAR DEVELOPMENT IN VITRO AND IN VIVO, POTENCY 
1.2.1 The Epigenetic Landscape 
“The epigenetic landscape” is a visualization of cellular differentiation that Conrad 
Waddington introduced in 1957, and consists of a mountain with ridges and valleys 
along its slopes (see figure 1). Waddington envisioned a completely undifferentiated 
cell – a totipotent cell – as a marble starting its journey of differentiation from the top 
of the mountain along the valleys all the way down to rest at the lowest points at the 
foot of the mountain while acquiring more and more features of a mature, differentiated 
cell as it loses potential energy (=potency). At certain points along the way, decisions 
are made as to which slope the cell should follow to which final fate. In his publication 
“The Strategy of the Genes”, Waddington also included another, less famous, image of 
the underside of the landscape, were genes are attached via strings that exert tension on 
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the landscape above. The tension varies depending on gene expression, which in turn 
depends on genetic and epigenetic traits as well as environmental cues, altering the 
topography of the landscape and changing the likelihoods of different outcomes in 
cellular differentiation. The first image became popular about a decade ago when 
Shinya Yamanaka and co-workers introduced the concept of induced pluripotent stem 
cells (iPSCs). By adding a defined set of transcription factors, Yamanaka managed to 
revert somatic cells back to pluripotency, which is often illustrated with an image of 
cells traveling up Waddington’s mountain, against the fictitious gravitational field. A 
more suitable homage to Waddington would be using the second image including the 
Yamanaka factors pulling the mountain from below at the top, inversing it, creating a 
local minimum were the top used to be (or actually close to the top: iPSCs are 
pluripotent, not totipotent). Nevertheless, the work of Yamanaka, and John Gurdon 
before him, on the reversibility of differentiation earned them the Nobel Prize in 
physiology or medicine in 2012, and initiated a whole new field of research with 
tremendous potential for both experimental biology and clinical applications. It also 
overturned the somewhat prevailing dogma that differentiation is a one-way street. 
 
 
Figure 1. Waddington’s epigenetic landscape. Left: The marble at the top represents a totipotent cell 
beginning its journey towards differentiation. Right: Gene expression alters the topography of the 
landscape. Images from “The Strategy of the Genes”, Waddington, 1957 (Waddington, 1957). 
 
1.2.2 In Vivo 
In the mammalian embryo, cell development is tightly controlled and progresses in an 
orderly sequence. This is accomplished by cross talk between neighboring cells (local 
induction) or distant signaling eventually leading to differential gene expression in cells 
destined for different fates. The ability of organisms to stop cells from travelling 
against the gravitational field of Waddington’s mountain is crucial to keep structural 
integrity and avoid neoplasm formation. Much of mammalian cell machinery is 
devoted to keeping cells in check, making sure that the only way to go is down the 
mountain, or into controlled cell death – apoptosis, and in that regard, to some extent, 
differentiation is a one-way street. There are four major ways for maintaining 
differentiation once it has been initiated (Gilbert, 2006): 
1. Transcription factors can act on the enhancer of its own gene, leading to 
independence of the signal that originally induced it. 
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2. Chromatin modification keeps the correct genes accessible and blocks access 
to inappropriate genes. 
3. Self-regulatory autocrine signaling maintains phenotype. 
4. Laterally enforced regulation: neighboring cells enforce the differentiation of 
each other. 
 
Much of the principles governing in vivo development can be directly applied to in 
vitro studies because of the robustness of the developmental machinery, but as the 
three-dimensional structure is lost, things certainly change. The process of specification 
in vivo, where cells acquire more mature features and eventually become post-mitotic 
(in the case of neurons), includes asymmetric cell division, where one daughter cell 
becomes more mature and the other one remains an un-specified progenitor cell. A 
symmetric cell division gives rise to two progenitor cells. In a relatively homogeneous 
cell culture in vitro, spatial organization of cells is disrupted, and the local cues, such as 
cell adherence molecules and morphogen gradients are absent or disturbed, which leads 
to less predictable mitotic results. The in vivo situation can, however, be partially 
mimicked by artificial morphogen gradients to achieve asymmetric cell division in vitro 
(Habib et al., 2013).  
 
1.2.3 Levels of Cell Potency: Totipotency, Pluripotency, Multipotency, 
Restricted Potency and Differentiated Progeny 
In mammals, the fertilized oocyte and the blastomeres of the first division(s) are 
totipotent, which means that they can give rise to embryonic as well as extra-embryonic 
tissue. But, according to the commonly used definition stating that the term “stem cell” 
denotes a cell that has the capacity to self-replicate, totipotent mammalian cells are not 
stem cells in vivo. Rather, they rapidly give rise to pluripotent stem cells and placental 
cells. Correspondingly, their developmental potential has not been captured in vitro. 
Pluripotency is commonly defined as a cellular state from which progeny of all three 
germ layers (ectoderm, mesoderm and endoderm) can be obtained. Although 
pluripotency, like totipotency, is a transient state in vivo, pluripotent cells can be 
derived from different stages of early embryonic development and maintained 
indefinitely in an artificially induced self-renewal state in vitro by supplementing 
exogenous cues (Nichols and Smith, 2012). In 2009, Nichols and Smith proposed two 
pluripotent phases: naïve and primed (Nichols and Smith, 2009). The naïve state is 
defined by the unrestricted developmental potential to give rise to all somatic lineages 
and the germline, exists only transiently in the preimplantation epiblast and is 
characterized, among a few other traits, by two active X chromosomes in female cells. 
In the primed state, one X chromosome is inactivated. The term primed alludes to the 
developmental pluripotent state that resembles the post-implantation embryonic 
configuration rather than the even less specified pre-implantation state. Cultured 
embryonic stem cells from rodents present the features of naïve stem cells, but 
conventional generation of embryonic stem cells from human blastocysts yields primed 
cells, representing a slightly more specified developmental stage, requiring in vitro 
manipulation with kinase inhibitors to reset them to the naïve state. Recently however, 
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the same group of researchers that defined the two different phases succeeded in 
deriving naïve cells from the inner cell mass of a human embryo (Guo et al., 2016).  
 
1.2.3.1 Pluripotency Network 
Some markers are differentially expressed in human naïve and primed pluripotent stem 
cells, but both cell types share expression of the transcription factors at the core of the 
pluripotency network, NANOG, OCT-4 and SOX2. These transcription factors (TFs) 
constitute a regulatory level of the transcriptional profile of the cell. In mammalian 
pluripotent cells, the core gene regulatory network actively maintains cells in a 
pluripotent state by repressing differentiation (Kalmar et al., 2009; Silva and Smith, 
2008). As well as acting on their own promoters, OCT-4 and SOX2 form heterodimers 
and bind to the proximal NANOG promoter, thereby creating cross-regulatory and auto-
regulatory transcriptional loops that maintain pluripotency through both activation and 
repression (Boyer et al., 2005; Pan et al., 2006; Rodda et al., 2005; Wang et al., 2006), 
reviewed in (Johnson et al., 2008). It has been shown that the core TFs do not act as 
pan-repressors of differentiation, but each factor controls specific fates. For instance, 
high levels of OCT-4 entail mesodermal differentiation and low levels ectoderm, in 
close interaction with the BMP4 signaling pathway. SOX2 represses mesendoderm 
differentiation whereas NANOG specifically represses ectoderm (Wang et al., 2012). 
Mouse ES cells expressing parts of the transcription factor network contribute poorly to 
chimaera formation compared to cells expressing all parts of the network (Toyooka et 
al., 2008), although studies of gene expression in hESCs at single cell level has 
revealed significant heterogeneity in the pluripotent stem cell compartment, showing 
that there is a gradient and a hierarchy of expression of pluripotency genes. Not all 
pluripotency-associated gene transcripts are found even in the population most likely to 
give rise to hESC colonies under conditions that promote hESC renewal. Rather than 
representing a binary choice, pluripotency and specification in hESCs exist along a 
continuum that is associated with an apparent probabilistic element of fate 
determination and interconversion between states (Enver et al., 2009; Hough et al., 
2009). 
 
1.2.3.2 NANOG 
NANOG is the first known transcription factor to appear after compaction in eutherian 
mammals, and its expression is down-regulated after implantation, precisely 
corresponding to the pluripotent phenotype in vivo (Chambers et al., 2003). When 
overexpressed in ES cells, NANOG is sufficient to sustain the pluripotency state in the 
absence of exogenously added leukemia inhibitory factor (LIF), a feature that no other 
TFs have been shown to possess (Chambers et al., 2003; Mitsui et al., 2003). NANOG 
levels undergo slow, random fluctuations, giving rise to heterogeneous cell populations 
without loosing pluripotency, but low NANOG expression entails higher propensity to 
differentiate (Chambers et al., 2007; Kalmar et al., 2009). However, in reprogramming 
of iPSCs, appearance of NANOG does not mark the fully reprogrammed state, as 
NANOG+ cells often do not give rise to human iPS cell colonies (Chan et al., 2009). 
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1.2.3.3 OCT-4 
While the function of OCT-4 in non-pluripotent cells has not been widely studied 
(although its presence in somatic cells has been questioned (Lengner et al., 2008)), its 
function in maintaining the pluripotent state of cells has been studied extensively for 
more than 25 years (Scholer et al., 1990; Nichols et al., 1998; Radzisheuskaya and 
Silva, 2014), and it is considered a master regulator for initiation and maintenance of 
pluripotency during embryonic development (reviewed in (Shi and Jin, 2010)). 
Pluripotency is maintained mainly by buffering the transcriptional activity of OCT-4, 
which also appears to be the main determinant to exit pluripotency (Munoz Descalzo et 
al., 2013) 
 
1.2.3.4 REX1 
The zinc finger transcription factor reduced expression 1 (REX1) displays similar, but 
not identical, expression pattern as OCT-4 in pluripotent cells in vivo (REX1 
expression is restricted to the ICM and is down-regulated in the epiblast and the 
primitive ectoderm), and is mostly absent from differentiated cells (Toyooka et al., 
2008; Mitsui et al., 2003). REX1 is tightly and directly regulated by NANOG and 
SOX2, which bind to REX1 promoter elements and cooperatively enhance 
transcription.  
 
1.2.3.5 Other Pluripotency-associated Markers 
Within the pluripotency continuum of hESCs in vitro, the growth factor GDF3 and the 
NODAL receptor TDGF-1 are the only proteins found selectively expressed by hESCs 
residing in the state suggested to be at the top of the pluripotency hierarchy (Hough et 
al., 2009). Some other secreted factors, such as CRIPTO and LEFTY, and receptors, 
such as CD133 and CD326, have also been positively associated with the pluripotent 
state (Abeyta et al., 2004; Boyer et al., 2005; Sundberg et al., 2009). The stage-specific 
glycolipid embryonic antigens SSEA-3, SSEA-4 are expressed by hESCs, but their 
function is unclear, and it has been shown that they are dispensable in maintaining the 
pluripotency in hESCs (Brimble et al., 2007). The glycan SSEA-5 and the keratan 
sulfate antigens Tra-1-60 and Tra1-81 are also expressed by hESCs with some degree 
of specificity (Schopperle and DeWolf, 2007; Tang et al., 2011). STELLA (DPPA3) is 
necessary for successful conversion of iPSCs (Xu et al., 2015), and signs of differential 
expression between naïve and primed pluripotent cells have been shown for STELLA, 
as well as for DPPA5, KLF17 and TFCP2L1 (Qian et al., 2016; Weinberger et al., 
2016; Ye et al., 2013). The DNA methyltransferase DNMT3B is expressed in 
pluripotent cells and down-regulated upon differentiation together with LIN28 and 
HESX1, although HESX1 is also expressed in several other tissues (Richards et al., 
2004; Watanabe et al., 2002). The Activin A signaling pathway has been shown to be 
indispensible for maintaining pluripotency (Vallier et al., 2009). 
 
1.2.4 Neural Stem, Progenitor and Restricted Precursor Cells 
Generally, the term stem cell is used for a cell with a seemingly unlimited capacity for 
self-renewal, whereas a progenitor cell gives rise to terminally differentiated progeny 
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after a finite number of mitoses, but there are no universally accepted definitions and 
researchers within different fields of biology use the terms differently (Seaberg and van 
der Kooy, 2003). Neural progenitor cells (NPCs) are multipotent, and can give rise to 
neurons, astrocytes and oligodendrocytes as well as self-replicate. In 1992, Reynolds 
and Weiss proved for the first time the existence of NPCs in adult mammals by 
demonstrating that adult mouse striatal cells could be propagated in vitro. They also, 
more or less by chance, developed the neurosphere culture assay, in which neural 
progenitors proliferate as free-floating spheres (see figure 2) without growth substrate 
(Reynolds et al., 1992; Reynolds and Weiss, 1992). Since then, the neurosphere culture 
assay has been used to culture and evaluate NPCs, sometimes with the aim to find a 
subpopulation that would constitute the true Neural Stem Cells (NSCs). NSCs are 
multipotent, slow dividing and self-replicate while giving rise to more committed 
progenitors. They are thought to constitute a small 
proportion of cells in neurosphere culture and have been 
suggested to make up the sphere-forming population in 
vitro (Capela and Temple, 2002; Cummings et al., 2005; 
Reynolds and Rietze, 2005; Tamaki et al., 2002; Uchida 
et al., 2000). In 2005, Reynolds and Rietze calculated the 
NSC frequency to be 0.16 % (Reynolds and Rietze, 
2005). The use of the neurosphere assay to determine the 
proportion of NSCs has, however, been questioned since 
neurospheres are highly motile and are prone to fuse and 
divide (Singec et al., 2006).  
 
 
Figure 2. Neurospheres derived 
from human fetal spinal cord in 
culture.
A number of markers have been proposed to label murine and/or human NSCs in vitro, 
including Prominin1 (CD133), LeX (CD15), Notch1, Syndecan-1 (CD138), β-1-
Integrin (CD29), CXCR4 (CD184) and FGFR4 (reviewed in (Ramasamy et al., 2013)). 
Conversely, a number of markers have been proposed to label progenitor cells more 
specified towards a certain lineage: glial progenitors express the ganglioside epitope 
A2B5 and the glycoprotein CD44 (Dietrich et al., 2002; Liu et al., 2004), and neuronal 
progenitors express the poly-sialylated neural cell adhesion molecule (PSA-NCAM) 
and the glycoprotein CD24 (Han et al., 2002; Lepore and Fischer, 2005; Mayer-
Proschel et al., 1997). Unspecified NPCs almost uniformly express the intermediate 
filament protein nestin (Lendahl et al., 1990). Ravin and co-workers showed in 2008 
that fate specification of rat neural progenitors to bi-potent (able to generate astrocytes 
and oligodendroglia) or uni-potent (generating either neurons or astrocytes or 
oligodendroglia) precursors in vitro occurs early, while cells are dividing in the 
presence of mitogens, implying that restricted precursor cells exist in vitro. 
Surprisingly, the specification was lost at passage, showing that progenitor fate 
restriction is reversible under certain circumstances, which certainly dilutes the 
meaning of the word “restricted” (Ravin et al., 2008). Nevertheless, the terms neural 
restricted precursors (NRPs) and glial restricted precursors (GRPs) have been widely 
used for cells expressing PSA-NCAM and A2B5, respectively (Cao et al., 2005; Cao et 
al., 2002; Davies et al., 2006; Haas and Fischer, 2013; Han et al., 2002; Han et al., 
2004; Lepore and Fischer, 2005; Lepore et al., 2004; Mayer-Proschel et al., 1997; Rao 
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and Mayer-Proschel, 1997; Sandrock et al., 2010). Many studies on specification of 
NSCs via NPCs and NRPs/GRPs to differentiated, mature cells have been conducted 
on rodent cells in vitro, and the translation to injury models has not been entirely 
straightforward. For instance, the injured spinal cord is far less permissive to neuronal 
maturation of transplanted neuronal progenitors than the uninjured cord (Cao et al., 
2002), and mouse neuronal precursors generate glial progeny after ectopic 
transplantation (Seidenfaden et al., 2006). The translation further to human cells has 
presented additional challenges vis-à-vis cell specification and marker specificity (Sim 
et al., 2009). For instance, A2B5 has been reported to co-localize with neuron-specific 
enolase (NSE) in human fetal brain cells (Satoh and Kim, 1995).  
 
Figure 4. Schematic 
representations of the 
hierarchy of potency of cells 
along the neuroectodermal 
lineage, as the hypothesis 
under which the studies in 
the present thesis were 
initiated. A pluripotent cell 
(magenta) gives rise to a 
multipotent neural 
progenitor (blue), which 
gives rise to restricted 
progeny, glial (green) and 
neuronal (red), which in turn 
generates terminally 
differentiated cells.  
 
 
 
 
1.2.5 Differentiated Cells 
The primary purpose and final goal of neural cell maturation is of course to generate 
functionally mature progeny that are properly incorporated in the tissue. Immature 
neurons are characterized by expression of the cytoskeletal proteins β-tubulin III, 
doublecortin (DCX) and microtubule-associated protein 2 (MAP2), while further 
maturation induces expression of neuronal nuclei antigen (NeuN), NSE and synaptic 
markers such as PSD-95, synaptophysin and synaptotagmin. In human spinal cord 
development, neuronal precursors leave the proliferative zone lining the central canal 
and undergo changes in transcription factor (TF) expression profile under the influence 
of dorso-ventral molecular gradients of Sonic hedgehog (SHH) and bone 
morphogenetic proteins (BMPs), secreted from the notochord and roof plate, 
respectively. Subtype specification is thus carefully governed by expression of 
mutually exclusive pairs of TFs depending on perceived concentrations of SHH and 
BMP (Jessell, 2000). Other secreted molecules, such as fibroblast growth factor (FGF) 
and retinoic acid (RA), induce simultaneous anterior-posterior identity specification via 
expression of homeobox (HOX) genes (Duester, 2008). Astroglial maturation in the 
human spinal cord occurs later, beginning at 6 weeks after conception, followed by 
oligodendrocyte maturation (Marklund et al., 2014). Astrocytes are characterized by 
glial fibrillary acidic protein (GFAP) immunoreactivity. Oligodendrocyte progenitors 
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express OLIG1, OLIG2, chondroitin sulfate proteoglycan (NG2) and platelet-derived 
growth factor α, while mature oligodendrocytes express myelin basic protein (MBP) 
and galactolipids (GALC, O1, O4) (Lu et al., 2001). The specificity of glial markers is 
generally low in humans. Cellular identity is confirmed based on functionality and 
morphology.  
 
 
Figure 3. Differentiated progeny of 
hscNPCs: GFAP-immunoreactive cells 
(green, presumably astrocytes), β-
tubulin III-immunoreactive cells (red, 
presumably neurons). Cell nuclei are 
counterstained with Hoechst (blue).
 
1.2.6 Sources of Neural Progenitor Cells 
1.2.6.1 Fetal Tissue 
The primary source of cells used in this thesis was human fetal CNS tissue from 
gestational week 5-11, specifically spinal cord and sub-cortical forebrain. The reason 
for excluding cortical cells is that the human cortex develops rapidly during 5-9 weeks 
after conception, from a thin cell layer at week 5 to making up the major fraction of the 
CNS at week 9, which makes it difficult to compare fetuses of varying ages using 
cortical material. Fetal tissue is only obtained after initial neuroectodermal specification 
has occurred, and the cells, although proliferating in vitro, are maintained within the 
neuroectodermal lineage. After about 9.5 weeks of gestation, the ability of human fetal 
spinal cord to generate viable stem/progenitor cultures is severely hampered (Akesson 
et al., 2007). 
 
1.2.6.2 Adult Human Tissue 
The regenerative capacity of the adult CNS in humans is very limited. Although 
various compartments of the adult CNS contain cells that posses proliferative ability, 
there seems to be very little production of neurons that actually incorporate into 
functioning neural networks after birth, certainly not in the cortex. Neurogenesis in the 
human hippocampus contributes to a turnover rate of 0.004 % daily in the dentate 
gyrus, but it is still unclear whether this exchange is of any significance for either 
normal brain function or disease progress (Bergmann et al., 2015). Nevertheless, cells 
from the subventricular zone of the lateral ventricle, the hippocampal granular zone, the 
filum terminale and a few other places of adult human CNS can be cultured in vitro and 
generate neurons (Nam et al., 2015). It has been suggested that adult stem cells is a 
preferred source of cells for clinical application, because of the possibility to do 
autologous transplantation – extract cells from the patient’s stem cell niche and 
transplant them back to the patient, with or without in vitro culturing. 
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1.2.6.3 Embryonic Stem Cells 
Neuroectodermal fate seems to be the default pathway of differentiating ESCs, 
although at protracted differentiation pace and with low yield (Kamiya et al., 2011). 
Media supporting neural cell growth can be used to enrich for neural progeny (Nat et 
al., 2007). More efficient differentiation can be accomplished by synergistic dual 
inhibition of the SMAD pathway with the BMP inhibitor Noggin and the molecule 
SB431542 (Chambers et al., 2009). It has been shown that ESC-derived NPCs retain 
self-renewal and neuronal differentiation potential to larger degree than fetal-derived 
NPCs, which lose neurogenic potential during extended culture and eventually undergo 
senescence (Anderson et al., 2007; Oikari et al., 2016; Wright et al., 2006). 
 
1.2.6.4 Induced Pluripotent Stem Cells 
Since they were first generated in 2006, iPSCs have held phenomenal promise for 
clinical use. The first clinical trial using iPSCs is currently ongoing, using autologous 
fibroblasts transformed into retinal pigment epithelial cells for transplantation to 
patients with neovascular age-related macular degeneration (Mandai et al., 2017). 
Similar neural induction methods as for hESCs can be used. No iPSCs were used in the 
present thesis. 
 
1.2.7 Growth Substrates 
Extracellular matrix molecules (ECM) provide structural and biochemical support to 
surrounding cells in vivo, and in vitro culture conditions designed to mimic the in vivo 
situation use the appropriate formulation of ECM when possible. All 2-dimensional in 
vitro studies containing live cells in this thesis were performed on growth substrates 
chosen to provide a situation similar to the in vivo setting while maximizing the 
survival of cells. To make the ECM stick to the plastic or glass surface, polyaminoacids 
are routinely used. Cells were also cultured as neurospheres (see section 3.2.2.1) 
without exogenously added growth substrates.   
 
1.2.8 Fluctuating Gene Expression 
A recurring theme throughout this thesis is transcriptional fluctuation generating 
phenotypic flexibility. Although on many levels tightly controlled, transcription of 
large parts of the genome is pulsating in transcriptional bursts with irregular intervals, 
but with surprisingly constant length and height of the pulses (Chubb et al., 2006) and 
with gene-specific kinetics (Suter et al., 2011). Stochastic gene expression has been 
linked to benefits of phenotypic variability (Acar et al., 2008; Kussell and Leibler, 
2005; Losick and Desplan, 2008). Speculation can be made that there are evolutionary 
benefits associated with limited random transcription if it, for instance, improves the 
ability to rapidly adapt to changing environmental conditions. Genes essential for 
cellular basic functions tend to have little noise in their expression patterns, while genes 
associated with stress responses are noisier (Blake et al., 2006). A little flexibility is 
good. A completely static system remains static. 
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2 AIMS OF THESIS 
The overall aim of the present thesis was to advance human neural stem cells towards 
spinal cord injury transplantation. 
 
The specific aims were as follows: 
• To compare fetal NPCs with hESC-derived NPCs over time in culture and with 
regard to safety and outcome after in vivo model injury transplantation, and to 
investigate features of fetal NPCs related to pluripotency 
• To study specification of NPCs 
• To develop and evaluate a method to dissociate cell aggregates suitable for 
GMP production of cells 
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3 MATERIALS AND METHODS 
 
3.1 ETHICAL CONSIDERATIONS 
All studies were conducted in accordance with the principles of the Declaration of 
Helsinki and with proper ethical permits from the Regional Ethics Vetting Board in 
Stockholm, Sweden, the National Board of Health and Welfare (“Socialstyrelsen”) and, 
were applicable, the Southern Stockholm Animal Experiment Ethics Board, Sweden. 
  
3.2 HUMAN FETAL TISSUE 
3.2.1 Obtaining Fetal Tissue 
Human fetal tissue was obtained from elective routine abortions (5.5-10.5 weeks after 
conception) in collaboration with the gynecology clinic at Karolinska University 
Hospital, Huddinge. Written, informed consent was given by the donors prior to 
donation of the abortion material. The donors were ensured that there would be no 
consequences coupled to their decision on participation in the research program apart 
from that a blood sample was required should they agree to participate. The blood 
samples were subjected to virology and serology screening. Experienced medical staff 
carried out the abortion procedures using gentle low-pressure aspiration, and the 
abortion material was age determined, categorized and dissected. Personal data were 
entered into a bio bank database and the tissue samples were assigned non-traceable 
serial numbers.  
 
3.2.2 Culturing Conditions for Fetal Cells 
3.2.2.1 Propagation 
In most experiments in the present thesis, cells from fetal spinal cord (sc) and 
subcortical forebrain (fbr) were used after careful removal of meninges and blood 
vessels. The tissues were separated and homogenized in neurosphere (NS) medium (1x 
DMEM/F12, (Life Technologies), 1x N-2 supplement (R&D Systems), 5 mM HEPES 
(Invitrogen), 0.6 % w/v glucose, and 2 µg/ml heparin (Sigma)) with a glass-Teflon 
homogenizer. Live and dead cells were counted in a Bürker chamber after addition of 
trypan blue, a dye that enters and labels cells with compromised membrane integrity, 
and therefore presumed dead, to a small aliquot of single cells using a phase contrast 
microscope. In a typical experiment, 1-2 million live cells and 2-4 million dead cells 
could be obtained from a spinal cord of gestational week 7 using this method, while a 
7-week sub-cortical forebrain typically generated 2-4 million live cells and 6-8 million 
dead cells. 
 
The single-cell suspensions were transferred to neurosphere growth (NSG) medium 
(NS medium supplemented with the mitogens endothelial growth factor (EGF, 20 
ng/ml), basic fibroblast growth factor (bFGF, 20 ng/ml) and ciliary neurotrophic factor 
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(CNTF, 10 ng/ml), all recombinant, from R&D Systems)) at a concentration of 100-
200 cells/µl and incubated at 37° C in a humidified atmosphere with 5 % CO2 in culture 
flasks or dishes. 20 % fresh medium was added twice a week. After a few days, 
neurospheres – spherical or almost spherical, free-floating cell aggregates – would form 
(see figure 2). 
 
When passaged, the neurospheres were enzymatically and mechanically dissociated 
using TrypLE Express (Invitrogen) and gentle trituration, and single cells were re-
seeded in fresh medium every 7-21 days depending on growth rate and sphere size.  
 
Passage of neurospheres with the Biogrid device described in paper IV was 
accomplished by aspirating neurospheres directly from the culture flasks through a 
plastic tube attached to the Biogrid, into a plastic 10 ml syringe and then ejected 
through the Biogrid again into fresh medium in new culture flasks. The 120-µM 
spacing between the sharp edges of the Biogrid allows small cell aggregates and single 
cells to pass, but cuts larger spheres.  
 
Adherent cultures were achieved by dissociating neurospheres and seeding the cell 
suspensions on polyornithin/laminin-111-treated surfaces at a concentration of 15,000 – 
30,000 cells/cm2, and culturing in NSG medium. The polyornithin (PO, Sigma) was 
diluted 1:6 in PBS, applied to the growth surface for 1 h, removed and allowed to dry 
for 10 min and subsequently rinsed 3x with autoclaved dH2O. 1 µg of laminin-111 
(Sigma) per cm2 was then added to the PO-treated surface in NSG medium and 
incubated at 37° C in a humidified atmosphere with 5 % CO2 for 24 h before use. The 
adherent cells were passaged by a method similar to that described for the 
neurospheres, using TrypLE Express-mediated dissociation from the surface and gentle 
mechanical trituration. Sphere cultures could be turned into adherent cultures and vice 
versa simply by adjusting the surface coating and replating.  
 
Spheres from both sc and fbr could readily be cryo-preserved in NS-medium 
supplemented with 30 % human serum albumin, 7.5 % dimethyl sulphoxide (DMSO) 
and 20 ng/ml EGF and put in the vapor phase of liquid nitrogen. Throughout all the 
studies, we have kept records of the number of passages and freeze-thaw cycles of all 
biological samples – henceforth referred to as cases – used, thus allowing correlation 
analysis of data to those factors. Experiments in the present thesis were performed 
using fetal cells passaged no more than 15 times and no less than twice, except when 
freshly acquired tissue was investigated specifically.  
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Figure 5. Routine 
procedures to obtain and 
culture fetal NPCs.  
 
 
 
 
 
 
Samples of fetal cultures were checked for karyotype abnormalities, and although most 
of them were found to be karyotypically normal, one case presented with the X-
monosomal karyotype 45,X, known as Turner syndrome. Since 3 % of all pregnancies 
start with 45,X embryos and 99 % of all Turner syndrome pregnancies result in 
spontaneous abortion during the first trimester, fetal samples collected during the first 
trimester will contain a larger proportion of Turner syndrome samples than the human 
population. The same can be argued for other karyotype aberrations (Urbach and 
Benvenisty, 2009). However, no evidence was found that large chromosomal 
alterations had been introduced in fetal cultures in vitro as a result of culture adaptation. 
The Turner case was excluded from studies in this thesis. 
  
3.2.2.2 Generation of Differentiated Neurons, Astrocytes and Oligodendrocytes 
To acquire progeny of differentiated phenotypes from multipotent progenitor cells, a 
number of media formulations were used. It is important to remember that there are no 
unbiased differentiation conditions. Simply removing mitogens from the culture 
medium induces various types of cell death and senescence rather than differentiation. 
3.2.2.2.1 Astrocyte-permissive Medium 
NS medium supplemented with fetal bovine serum (FBS) promotes glial growth and 
maturation. 10 % FBS was routinely used and cells were plated on poly-D lysine-
coated glass slides in 24-well plates at a concentration of 1.5x105 cells/cm2 for 12 days. 
3.2.2.2.2 Neurobasal Medium (NBM) 
NBM is a proprietary cell culture medium designed to increase the survival of 
embryonic hippocampal rat neurons and is now widely used for many types of neural 
cell cultures. B27 supplement was added 1:100 and cells were plated on poly-D lysine- 
and fibronectin-coated glass slides in 24-well plates at a concentration of 3x105 
cells/cm2 for 12 days. 
3.2.2.2.3 NS-medium with Serum Replacement (SR) and Retinoic Acid (RA) 
In paper III, NS medium supplemented with 5 % SR and 10 µM RA (NS-SR-RA), 
which promotes neuronal differentiation, was used. Cells were plated on poly-D lysine- 
and fibronectin-coated glass slides in 24-well plates at a concentration of 3x105 
cells/cm2 for 12 days. 
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3.3 HUMAN EMBRYONIC STEM CELLS (hESCs) 
3.3.1 Obtaining hESCs 
hESCs were derived from surplus embryos donated by couples undergoing infertility 
treatment at the fertility unit of the Karolinska University Hospital. Supernumerary 
embryos of high quality are cryopreserved for a period of five years, after which the 
patients get to decide whether the embryos should be discarded or be donated for 
research. Embryos of low quality can be donated or discarded immediately after 
generation and evaluation. 
 
3.3.2 Culturing Conditions for hESCs 
3.3.2.1 hESCs on Feeders 
Human foreskin fibroblasts (HFFs) were used as feeder cells, providing auxiliary 
substances including attachment substrates, nutrients and other factors needed for hESC 
growth in culture. HFFs were cultured on Iscove’s Modified Dulbecco’s Medium 
(IMDM) supplemented with 10 % FBS and 25 U/ml penicillin/streptomycin (PEST, 
Cambrex Bio Science). HFFs were irradiated (40 Gy) to stop their proliferation, and 
the medium was gradually changed into hESC medium, consisting of KnockOut 
Dulbecco’s Modified Eagle’s Basal Medium (kDMEM) supplemented with 20 % 
Knockout Serum Replacement (kSR), 2 mM GlutaMax, 25 U/ml PEST, 1 % minimal 
essential medium non-essential amino acids, 0.5 mM β-mercaptoethanol and 8 ng/ml 
human bFGF, and hESCs, freshly passaged either by mechanical cutting or dissociation 
with TrypLE and gentle trituration, were put on the feeders. At passage with TrypLE, 
the feeder cells create gelatinous clumps that can be removed, and the hESCs can be 
transferred as single cells in solution. Contaminating feeder cells die after a few days 
after passage. All cultures were maintained in a humidified atmosphere at 37° C and 5 
% CO2.  
3.3.2.2 hESCs on Chemical Substrates 
Culturing hESCs on chemical substrates is believed to be of importance for future 
clinical translation, avoiding possible transfer of pathogens from feeder cells or feeder 
cell contamination. The support normally given by feeder cells is replaced with 
nutrients added to the media. In this thesis, Matrigel and Laminin-511 were used as 
substrates and the medium mTeSR (STEMCELL Technologies) was used with 
TrypLE-mediated passaging. 
 
3.3.2.3 hESCs as Spheres 
In paper IV, suspension cultures of hESCs were established as described by Steiner 
and collaborators (Steiner et al., 2010). Cell aggregates were mechanically removed 
with a scalpel from colonies of undifferentiated hESCs grown on feeders. The 
aggregates were placed in 10 cm2 ultra low attachment plates in 2 ml of the 
suspension medium containing NBM with 14 % kSR, 2 mM glutamine, 50 U/ml 
PEST, 1 % minimal essential medium non-essential amino acids and 4 ng/ml bFGF. 
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The medium was replaced every second day by tilting the plate and removing 50–80 
% of the medium and adding a fresh medium. Cell aggregates were initially passaged 
every 7 or 8 days using a 1 ml pipette to break up the aggregates into smaller clusters. 
Dissociation performed using the Biogrid device described in paper IV was done by 
replacing most of the cell culture medium and aspirating the spheres through the 
Biogrid at an approximate flow rate of 1 ml/s and immediately ejecting the cut 
spheres back into the well.  
3.3.3 In Vitro Differentiation of hESCs 
3.3.3.1 hESCs Induced to Neural Progenitor Cells – hESC-NPCs 
To induce neural specification, hESC colonies grown on laminin, Matrigel or feeders 
were mechanically dissected into two different media in suspension culture: neural 
differentiation medium (NDM) and neural stem cell medium (in paper I called NSM, 
throughout the rest of this thesis called NSG). NDM contained DMEM/F-12 and 
NBM (1:1) supplemented with 1xB27, 1xN2, 2 mM GlutaMax (Gibco Invitrogen), 25 
U/ml PEST, and 20 ng/ml bFGF. The neurospheres obtained were mechanically split 
by cutting with a scalpel once a week and cultured up to 20 weeks.  
3.3.3.2 Terminal Differentiation of hESC-NPCs 
Differentiated neural progeny of hESC-NPCs were generated using the same protocols 
for differentiation as described for fetal cells under section 3.2.2.2. 
 
3.4 TERATOMA TEST 
In paper I, to study teratoma formation, 10–12 intact neurospheres (in total ≈100,000 
cells) derived from hESCs and human fetal CNS were transplanted into the right 
testis of severe combined immunodeficiency (SCID) mice (n = 10), as previously 
described (Hovatta et al., 2003; Inzunza et al., 2005). Equivalent subcutaneous 
transplantations of 10–12 neurospheres (≈100,000 cells) in the left groin were also 
performed in the same animals. Undifferentiated hESCs of the same cell lines 
(100,000 cells/injection) were used as positive controls. After the cell injections, the 
development of tumors in the testes and subcutis in transplanted animals was 
followed by manual palpation during 12 weeks. Animals were sacrificed by a lethal 
dose of intravenous barbiturates before transcardiac perfusion with 4 % PFA in 0.1 M 
PBS. Testes were dissected out and a 1 cm2 piece of the skin and superficial layer of 
underlying skeletal muscle at the location of the subcutaneous transplantation was cut 
out, the tissue was post-fixed for 4 h in PFA, and then transferred to 10 % sucrose for 
a minimum of 24 h. Sections (10 µm) were cut on a cryostat (Micron) and stained 
with hematoxylin-eosin (Sigma) for histological analysis. Immunohistochemistry was 
performed as described in section 3.6.1.  
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3.5 REVERSE TRANSCRIPTASE – POLYMERASE CHAIN REACTION 
(RT-PCR) AND QUANTITATIVE PCR (qPCR) 
3.5.1 RNA Extraction and cDNA Synthesis  
In paper I, RNA was extracted from hESC-NPCs and fetal NPCs using the 
RNeasy® Micro Kit (Qiagen). RNA was quantified using a NanoDrop 
spectrophotometer. 50 ng of RNA was used for cDNA synthesis using oligo-dT 
primers at 50° C in a total reaction volume of 25 µl. In paper II, new primers were 
designed using Vector NTI and Primer3 software to span exon-exon boundaries and 
were checked for sequence homologies using NCBI BLAST. RNA was extracted 
using the RNeasy Mini Kit (Qiagen). Cells were pre-homogenized by passage 
through a 20-gauge needle in lysis buffer 10 times. 100 ng of RNA was used for 
cDNA synthesis using target-specific reverse primers for PCR and random hexamers 
for qPCR. The reverse transcription reactions using target-specific primers were 
performed at 55° C (NANOG, OCT-4, DNMT3B, CRIPTO), 50° C (GDF3, GAPDH) 
or 51° C (REX1) in 25 µl, and at room temperature with random hexamers. 
3.5.2 PCR  
In paper I, each PCR reaction contained 1 µl of cDNA, corresponding to 2 ng of 
RNA, and the PCR program included: denaturation in 95° C for 3 min followed by 35 
cycles of 95° C for 30 s, 55° C for 30 s, 72° C for 1 min, and final extension for 5 min 
at 72° C. Primers designed to amplify the transcripts of the following genes specific 
for the following cell types of interest were used a) pluripotent cells: NANOG, OCT-
4, DNMT3B, Activin A receptor; b) mesodermal cell lineages: Brachyury, endodermal 
cell lineage: alpha-fetoprotein (AFP); c) NPCs: SOX2, NESTIN, PAX-6, MUSASHI, 
MASH1, neural cell adhesion molecule (NCAM); d) radial glial cells: brain lipid 
binding protein (BLBP); e) neuronal cells: Doublecortin (DCX), MAP2, β-tubulin III; 
f) astrocytes: glial fibrillary acidic protein (GFAP); g) oligodendrocytes: OLIG1, 
OLIG2. The housekeeping gene GAPDH was used as reference gene. The expression 
of the genes was analyzed at 2, 4, 6, 8, and 12 weeks of culture. In paper II, The PCR 
reaction was performed with Stratagene Paq 5000 DNA polymerase. The products 
were run on agarose gels, and single bands were obtained, cut out, purified using the 
QIAquick gel extraction kit (Qiagen) and sequenced to confirm the identity of the 
original mRNA. Negative controls included ‘no template’ and ‘no reverse 
transcriptase’ samples. 
 
3.5.3 qPCR  
Quantitative RT-PCR (qPCR) was performed with FastStart Universal SYBR Green 
Master Mix (ROX, Roche) for the genes OCT-4, DNMT3B, GDF3, REX1 and 
GAPDH, and with a TaqMan assay for NANOG (Applied Biosystems). Primers for 
SYBR Green chemistry were designed specifically for qPCR and ordered from 
Thermo Electron GmbH (Germany), and primers and probes for NANOG were 
custom designed by Applied Biosystems. Primers were designed to span exon–exon 
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boundaries, and primer sequence specificity was confirmed with NCBI BLAST to 
eliminate the risk of genomic contamination. Primers were analyzed with PCR; 
amplified products were run on agarose gels, cut out, and sequenced. qPCR was 
performed using the 7500 Fast Real-Time PCR System (Applied Biosystems) with 
the following profile: 1 cycle of 95°C for 10 min, 40 cycles of alternating 95°C for 15 
s, and 60°C for 30 s followed by a melting curve analysis for specificity control. The 
quantification was performed using the Pfaffl (∆∆Ct) method as described in (Bookout 
et al., 2006) using pooled undifferentiated hESCs HS999 and HS980 as a reference 
sample and GAPDH as reference gene. Software-generated thresholds and Ct values for 
each gene were used (7500 Fast System version 2.0.3). The amplification efficiencies 
were obtained by running a dilution series of hESC mRNA and used to calculate 
relative fold induction with the formula fold induction = !"#$!∆!"!(!"#$%"&!!"#$%&)!"#$!∆!"!(!"#$%"&!!"#$%&)  
 
where 
 
Eampt = Amplification efficiency for the target gene = PCR efficiency for the target 
gene + 1 
Eampr = Amplification efficiency for the reference gene = PCR efficiency for the 
control gene + 1 
∆Ctt (control-sample) = Cycle number at which the signal from the target gene in the control 
sample reaches the threshold minus the cycle number at which the signal from the 
target gene in the sample reaches the threshold 
∆Ctr (control-sample) = Cycle number at which the signal from the reference gene in the 
control sample reaches the threshold minus the cycle number at which the signal from 
the reference gene in the sample reaches the threshold. The data analysis was 
performed with Microsoft Excel. See papers I and II for lists of primers. 
3.6 IMMUNOCHEMISTRY  
All methods in the following sections (immunohistochemistry, immunocytochemistry, 
FACS and flow cytometry) rely on antibodies produced by immunized animals. 
Antibodies specifically bind the desired target epitopes with varying affinities, and, 
importantly, also display cross-reactivity to similar epitopes on other proteins as well as 
unspecific binding of other parts of the antibody than the antigen-binding site. For all 
techniques using antibodies in surplus, the signal from the specific binding 
asymptotically reaches a maximum value as all epitopes are occupied. The signal from 
the unspecific binding increases quasi-linearly with increasing concentration. Titration 
of appropriate antibody concentration is performed to maximize the proportion of 
specific, desired, binding to unspecific, undesired binding (see figure 6). Different 
methods to decrease unspecific binding can also be implemented. Problems regarding 
antibody-generated signal noise inherent to individual techniques are further discussed 
in the sections below. 
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Figure 6. Signal output and specificity of immunochemistry. For all methods using antibodies, the 
specific binding reaches a maximum as epitopes get occupied (black line). The unspecific binding 
(background) increases quasi-linearly (grey line). The obtained signal is shown in dark grey. Optimal 
antibody concentration and staining conditions must be determined individually and should maximize 
discrimination of specific from unspecific binding. 
 
3.6.1 Immunohistochemistry 
In a typical immunohistochemical analysis, the tissue was fixed in 4 % formaldehyde 
solution (PFA), treated with 30% sucrose over night at 4° C, mounted in TissueTek 
mounting medium (Sakura Finetek), and frozen on dry ice. In paper I, neurospheres 
were sectioned in a cryostat at a thickness of 5 µm. Tissue sections were blocked with 
1.5 % goat/donkey serum in PBS at 30 min in room temperature (RT), and primary 
antibodies were diluted in 0.3 % Triton X-100 in PBS and incubated overnight at 4° 
C. After rinsing in PBS the sections were incubated with secondary antibody in 0.3% 
Triton X-100 PBS for 1 h at RT. To detect neurons, anti-β-tubulin type III (1:800, 
Sigma) and anti-MAP2 (1:50, Chemicon) antibodies were used; to detect immature 
cells, anti-BLBP (1:500, Chemicon) and anti-nestin (1:200, Chemicon) antibodies 
were used; to detect astrocytes, anti-GFAP (1: 500, DAKO) antibody was used. 
Secondary antibodies used were Cy3-conjugated AffiniPure goat anti-mouse IgG 
(1:2400, Jackson Immuno Research Laboratories), Alexa Fluor 488-conjugated goat 
anti-mouse IgG, and Alexa Fluor 488-conjugated goat anti-rabbit IgG (1: 1200, both 
from Molecular Probes). For nuclear counterstaining, Hoechst 33342 (1: 200, Sigma) 
was used. For negative control, samples were incubated with secondary antibody 
only. At least five sections/sample were analyzed. For paper I, analysis was 
performed on hESC-NPCs cultured in NSM and NDM, and human fetal NPCs 
(hfNPCs) cultured in NSM in vitro for 2, 4, 8, 12, and 20 weeks. Samples were 
evaluated semi-quantitatively using a fluorescence microscope (Zeiss, Axiophot). 
Human cells in the teratoma tests in paper I were detected using human nuclear 
marker HuNu (1:250, Chemicon) and differentiated hESC-NPCs using anti-β-tubulin 
III (1:800, Sigma) antibody.  
Human fetal spinal cord (paper III) was fixed in 4 % PFA, cryo-preserved in 30 % 
sucrose, mounted and frozen as described for neurospheres above. For paper I, rat 
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spinal cords were perfusion fixed with 400 ml of 4 % PFA in phosphate buffer, pH 
7.4, followed by excision, postfixation in 4 % PFA for 90 min, rinse and storage in 30 
% sucrose. 10 µm sections were cut on a cryostat.  
3.6.2 Immunocytochemistry  
Adherent cell cultures were washed with PBS, fixed in 4 % PFA for 10 min, washed 
3x5 min with PBS, blocked in 1.5 % serum from the animal the secondary antibody 
was produced in in 0.3 % Triton-X in PBS for 30 min. Primary antibodies were diluted 
in block and samples were incubated over night at 4° C and washed with 0.1 % triton in 
PBS 3x5 min the next day.  Incubation with the appropriate secondary antibodies in 
block for 1 h was followed by 3x5 min wash in 0.1 % triton in PBS. A DAPI:PBS 
1:50,000 solution was added for 1 min and removed before the cells were mounted in 
PVA mounting media (DABCO) and analyzed using a Zeiss fluorescence microscope 
with OpenLab software. The primary antibodies used were NANOG AF1997 Goat 
(R&D Systems), OCT-4 C-20 Goat (Santa Cruz Biotech), REX-1 AP2051a Rabbit 
(Abgent). Secondary antibodies: Rabbit anti-goat Alexa488 (Invitrogen Molecular 
Probes), Rabbit anti-goat Alexa488 (Invitrogen Molecular Probes) and goat anti-rabbit 
Cy3 (Jackson Immuno Research). 
 
3.7 FLOW CYTOMETRY AND FLUORESCENCE-ACTIVATED CELL 
SORTING (FACS) 
Flow cytometry relies on specific labeling of cells by e.g. antibodies coupled to 
fluorescent proteins or reporter gene expression with fluorescent proteins. The 
technique allows analysis of single particles – in this case cells – in solution. A narrow 
stream of the solution is created with the help of a carrier (sheath) fluid so that cells 
come in single file. The stream is directed through a laser beam orthogonal to the 
stream. Detectors appropriately placed outside the flow chamber analyze the refracted 
and fluorescent light. The different parameters detected are Forward Scatter (FSC), 
roughly reflecting cell size; Side Scatter (SSC), representing cell granularity and 
fluorescent light intensity. 
 
In papers II and III, FACS was used to sort out subpopulations of live cells from 
heterogeneous populations. The method allows simultaneous analysis of single cells by 
flow cytometry and sorting of cells. The stream of sheath fluid carrying cells in single 
file passes through a rapidly oscillating nozzle head, creating droplets. Flow speed is 
adjusted to maximize the probability that each droplet contains one cell. Depending on 
set parameters, droplets are given a small electrical charge, allowing sorting by an 
electrostatic field acting on the droplets (see figure 7). PBS was routinely used as 
sheath fluid. 20 PSI (pounds per square inch ≈ 1.4 bar) sheath pressure and a 100 µm 
nozzle was found to be optimal for cell survival and FACS efficiency.  
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Figure 7. FACS basics. 
 
Spectral overlap of fluorescent species requires careful consideration when designing 
flow cytometry experiments. Primarily, fluorescent molecules with minimal spectral 
overlap were combined when possible (e.g. allophycocyanin – APC, and phycoerythrin 
– PE), and proper compensation between fluorescent channels was implemented. 
Compensation is the process of correcting the spillover from the primary signal in each 
of the other detectors, rendering the signal identical to background in all inappropriate 
detectors. This was accomplished by using unstained sample controls for setting 
background, single stained sample controls and FMO (fluorescence-minus-one) 
controls, each containing all fluorescent species included in the experiment except one, 
for which the compensation of that particular channel was adjusted so that the signal 
was identical to background.  
 
Dissociation of cell aggregates before FACS comes with an inherent conflict between 
efficiency of separation and cell viability. Thorough dissociation inevitably yields a 
proportion of dead cells, most of which were distinguished from live cells by their 
compromised membrane integrity and inability to exclude the DNA-binding 
fluorescent agent Sytox® Blue (Molecular Probes). In some experiments, LIVE/DEAD 
Cell Viability Stain (Molecular Probes), which binds protein rather than DNA, and can 
therefore distinguish dead cells from live cells even after permeabilization and fixation, 
was used for exclusion of dead cells. Remaining doublets or larger aggregates were 
excluded by analyzing their FSC-H (forward scatter height) versus FSC-A (forward 
scatter area) signal ratio. A properly calibrated cytometer yields almost the same value 
for a spherical object in FSC-H and FSC-A, meaning that non-spherical objects, such as 
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aggregates of two or more cells, will deviate from the diagonal in an FSC-H vs. FSC-A 
signal plot.  
 
FACS was performed on a Becton Dickinson (BD) FACSDiva and on a BD FACSAria 
Fusion. Flow cytometry analysis was performed on a BD LSRFortessa, a BD Accuri 
C6 and on a BD FACSCalibur. Bead calibration was performed before every FACS 
experiment and regularly on analysis machines. Immediate post-sort analysis was 
performed after FACS experiments to determine the purity of the sorted populations. In 
paper II, single cell sort mode was used for reporter-transduced cells, and purity mode 
for CD133/CD24 sorting. In paper III, purity mode was used for all FACS experiments 
except the CTV experiment (see section 3.12), in which yield mode was used. 
 
Target antigen Method Dilution Source Used in paper 
A2B5 FC 1:50 R&D Systems I, IV 
A2B5-APC, PE FC 3:100 Miltenyi I, IV 
BLBP ICC 1:500 Chemicon I 
CD133-PE FC 3:100 Miltenyi I, III, IV 
CD15-PC5 FC 3:100 Beckman Coulter I, IV 
CD24-PerCP-Cy5.5 FC 1:50 BD III, IV 
CD326 FC 1:100 Chemicon I 
CD44-PE FC 1:50 BD Pharmingen I 
CD45-FITC FC 1:100 BD III 
CD56-PC5 FC 1:50 BD Pharmingen I 
GFAP ICC, IHC 1:500 Dako I-IV 
DCX ICC 1:500 Abcam IV 
HuNu IHC 1:250 Chemicon I 
Ki67 ICC 1:100 DAKO II 
MAP2 ICC 1:50 Chemicon I 
NANOG ICC 1:100 R&D Systems III 
Nestin ICC, IHC 1:200 Chemicon I 
Nestin ICC 1:400 Millipore IV 
OCT-4 FC, ICC 1:200 Santa Cruz III 
PSA-NCAM-APC, PE FC 3:100 Miltenyi I, IV 
PSA-NCAM FC, ICC 1:400 Milipore I, IV 
REX1 IHC 1:200 Abgent III 
SSEA-4 FC 1:100 Millipore I 
β-tubulin III ICC, IHC 1:800 Sigma I-IV 
β-tubulin III ICC 1:1200 Biosite IV 
Table 1. List of antibodies used in the present thesis. 
 
3.8 BATCH SPHERE COUNTING BY PHOTO ANALYSIS 
For large-scale, unbiased image analysis of sphere sizes and sphere number, phase 
contrast images were obtained using an Olympus IMT-2 inverted microscope with an 
Olympus CMOS camera in 9 pre-determined positions in each circular 10 cm2 well. A 
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schedule of well positions was created by recording the number of turns of the stage 
control knobs needed to cover as much of each well as possible, while avoiding 
including the edges of the wells that otherwise could distort the image, and so that 
including any part of the well in more than one photo was avoided. Standardization was 
achieved by placing the culture plate edge in parallel with the edge of the microscope 
stage, aligning the leftmost edge of the well in the eyepiece crosshair and turning the 
stage control knobs according to the pre-determined schedule. Focus was adjusted 
manually. 
 
The resulting images required pre-processing before analysis to distinguish background 
and debris from spheres, and to generate binary (black-and-white) images. All images 
from one well were put in a separate folder and, typically, four wells of each condition 
were analyzed. This allowed for estimation of the technical variance and evaluation of 
the method. Three and eight biological replicates were used in paper II and paper III, 
respectively. 
 
The following ImageJ macro was used to count spheres and to analyze individual 
sphere sizes in all images in a folder chosen by the user:  
macro "Batch Measure" { 
    dir = getDirectory("Choose a Directory "); 
    list = getFileList(dir); 
    setBatchMode(true); 
    for (i=0; i<list.length; i++) { 
        path = dir+list[i]; 
        showProgress(i, list.length); 
        if (!endsWith(path,"/")) open(path); 
        if (nImages>=1) {run("Find Edges"); 
   run("Enhance Contrast", "saturated=0.5"); 
   run("Subtract Background...", "rolling=50"); 
   run("Make Binary"); 
   run("Outline"); 
   run("Fill Holes"); 
   run("Find Edges"); 
   run("Analyze Particles...", "size=200-Infinity 
circularity=0.60-1.00 show=Outlines display exclude summarize record"); 
            close(); 
        } 
    } 
}     
 
The data output given by this ImageJ macro is the number of circular (with a 
circularity=4π(area/perimeter2)> 0.6) objects larger than 200 pixels in each picture and 
their individual two-dimensional size in pixels, enabling the quantification of spheres as 
well as individual and total sphere volume (assuming that all neurospheres are perfect 
spherical objects), which can be considered to be directly proportional to the number of 
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cells (assuming that all spheres have equal and homogenous cell densities). Data 
compilation, calculations and statistical analysis were performed using Microsoft 
Excel.  
 
 
 
 
Figure 9. a) Phase-
contrast images of 
spheres. b) Images 
processed in ImageJ 
using the batch 
sphere counting 
macro described in 
section 3.8. 
 
 
 
3.9 TRANSCRIPTOME ANALYSIS  
In order to compare the transcriptomes of cells immunoreactive for different markers 
associated with glial or neuronal phenotype commitment at sorting and after the re-
setting of the immunoreactivity profile three passages later, cells were FACS-sorted 
based on A2B5 and PSA-NCAM immunoreactivity as described above. 50,000 cells of 
each of the four populations flow-through (FT), double negative (-/-), A2B5+/PSA-
NCAM- (A+/P-) and A2B5-/PSA-NCAM+ (A-/P+) from four different hscNPC cases 
(biological replicates) were sorted directly into 300 µl of RNAlater (LifeTechnonogies) 
and frozen at -80°C before RNA extraction. 50,000 cells per population were also 
sorted directly into NSG medium, cultured adherently for one passage and 
subsequently as spheres for two more passages before RNA extraction, generating a 
total of 32 samples (four populations from four biological replicates measured at two 
time points). RNAlater was removed by addition of 300 µl PBS and centrifugation at 
16,000 x g. RNA extraction of sorted cells was done with the RNeasy Micro Kit 
(QIAGEN) according to the manufacturer’s instructions. RNA extraction of cultured 
cells was done with TRIzol/chloroform separation after which RNA in the hydrophilic 
phase was transferred to PureLink RNA Mini Kit (Ambion) columns and eluted 
according to the manufacturer’s instructions. RNA quality was determined on a 
BioAnalyzer 2100 with the Agilent RNA 6000 Pico Kit (Agilent Technologies). RNA 
quantity was determined using the Qubit® RNA HS Assay Kit (ThermoFischer 
Scientific). 
b)
a)
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The RNA samples were further processed using the Illumina® TotalPrep™ RNA 
Amplification kit according to the manufacturer´s instructions. Briefly, 80 ng total 
RNA was subjected to reverse transcription using oligo(dT)-primers to synthesize first 
strand cDNA, followed by a second strand synthesis to generate double-stranded 
(ds)DNA, which was then purified on column. In vitro transcription of cDNA 
generated multiple copies of biotinylated antisense cRNA, which was purified on 
column, quality-checked as described above and quantified using a NanoDrop™ 
spectrophotometer. Biotinylated cRNA was hybridized to the HumanHT-12 v4 
Expression BeadChip Kit (Illumina) according to the manufacturer’s instructions. 
Preliminary quality control was performed using the Illumina BeadStudio software. 
Data were processed in R using the Limma package from Bioconductor. Probes with 
signal intensity higher than 5 on a log2 scale compared to background in at least three 
samples were considered expressed and retained for downstream analysis, keeping 
32,456 out of 47,323 probes. Differentially expressed genes were obtained by blocking 
the donor factor, yielding a paired samples analysis, comparing the transcriptome of 
sorted cells immediately after sorting to that of the same, sorted culture three passages 
later. 
 
3.10 LENTIVIRAL TRANSDUCTION OF REPORTERS 
To investigate whether transcripts of pluripotency-associated mRNA were evenly or 
unevenly distributed among NPCs, reporter lentiviral constructs for Nanog and Oct-4 
expressing GFP and Rex1 expressing RFP under specific promoters were used in 
paper II. In paper II and III, control viruses with a constitutively active promoter 
(EF1α) expressing GFP were used. All viruses were from Allele Biotechnology Inc. 
Viruses were transduced into newly passaged adherent cell cultures. The positively 
charged poly-cation hexadimethrine bromide (Polybrene) was added to facilitate virus 
envelope binding to the cell membrane at a concentration of 2 µg/ml. A multiplicity 
of infection (MOI) virus ratio >3 was employed, which typically yielded >95 % 
transduction efficiency in control experiments with control viruses without a 
discernible effect on cell survival or proliferation. The viruses and Polybrene were 
removed by extensive rinsing with NSG medium after 24 h and subsequent 
passaging.  
3.11 LIVE-CELL IMAGING  
In paper II, live-cell imaging of reporter-transduced NPCs in a humidified 
atmosphere at 37° C with 5 % CO2 was done by acquiring time-lapse movies using a 
Zeiss Cell Observer system with a 10x objective, rendering photos with a 150 x 120 
µm surface area (=1,388 x 1,040 pixels x 1.1 µm resolution/10x magnification) 
containing between approximately 10 and 100 cells each. Locations were chosen non-
randomly where live, fluorescent cells were present. Phase contrast images and 
fluorescence images were obtained. Thorough optimization was performed, since 
live-cell imaging requires compromises between what is good for the cell cultures and 
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what generates high quality images. High excitation intensity, frequent image 
acquisition and long exposure time effectively kills cells (Schroeder, 2011). The image 
intervals were typically 7.5 min, and the cultures were monitored for 24 h. The image 
analysis was performed with ImageJ using the LSM Reader plugin and with Adobe 
Illustrator CC.  
3.12 ANALYSIS OF CELL EXPANSION 
In paper III, to determine if cell division is necessary for interconversion to occur, or 
whether clonal expansion or culture adaptation is responsible for the re-setting of 
proportions of cells expressing different antigens, single cells were labeled with 
CellTrace Violet (CTV), anti-CD133 and anti-CD15 antibodies and subsequently 
sorted with FACS and then cultured in NSG medium to allow the antigen profiles of 
sorted hscNPCs to reset. Dead cells were excluded in the FACS analysis on the basis of 
LIVE/DEAD fluorescence. CTV content decreases as cells proliferate, diluting the 
fluorescent signal for each cell division. This allows for analysis of accumulated 
proliferation over a longer period of time. At first and third passage after sorting (10 
days and 33 days after sorting, respectively), cells were analyzed with flow cytometry 
for expression of the same markers used for sorting correlated to CTV content, with the 
purpose of determining if cells that had interconverted also had undergone a higher 
number of mitoses.  
 
3.13 BIOGRID FABRICATION 
Silicon microgrids were fabricated at Lund University by anisotropic wet etching with 
conditions and dimensions listed in paper IV.  
 
3.14 ANALYSIS OF PRESSURE EXPOSURE TO SPHERES USING 
BIOGRID 
In paper IV, pressure changes occurring during normal Biogrid passage were measured 
using a differential pressure sensor connected via a three-way connection to the Biogrid 
setup. To study neurosphere pressure tolerance, the three-way connection was switched 
to connect the sensor to the syringe, closing the outlet tubing, after which pressure 
transients were applied by aspiration or compression.  
 
3.15 VIABILITY ASSAY 
In paper IV, cell viability was evaluated with the LDH assay, in which the activity of 
the enzyme lactate dehydrogenase (LDH) is measured. LDH leaks from apoptotic or 
necrotic cells. By analyzing its activity in the medium, the level of cell death can be 
estimated. The method uses a coupled enzymatic reaction, where a tetrazolium salt is 
converted into a red formazan product by the enzyme diaphorase using the NADH 
generated from NAD+ by LDH when converting lactate to pyruvate (see fig. 10). The 
formazan content was analyzed with a microplate photometer at 492 nm absorbance 
using absorbance at 650 nm as reference. Confounding factors include medium 
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additives with LDH activity and/or absorbance at 492 nm. 
 
Figure 10. Principle of cell 
viability analysis with LDH. 
The activity of LDH in the 
medium is measured via a 
coupled enzymatic reaction 
generating a red formazan 
product, which is measured 
spectrophotometrically.  
 
 
3.16 SCI IN VIVO MODEL 
A total of 24 adult immunodeficient female rats (170–200 g, HsdHan:RNU-rnu) were 
included in paper I. After a laminectomy of thoracic vertebra 9, a spinal cord 
contusion injury was produced using the IH Spinal Cord Impactor set at a force of 
150 kilodynes, with no dwell time. The lesioned spinal cords were covered with one 
layer of Lyoplant meningeal substitute prior to suture of the wound. Eight days later 
the animals were re-anaesthetized and 10–12 hESC-NPC neurospheres (cultured for 8 
weeks to allow neural induction) selected by size to contain a total of approximately 
100,000 cells were transplanted to the lesion area. Three groups of injured rats (6 
animals/group) were included and transplanted with: a) hESC-NPCs cultured in 
NDM (HS360), b) hESC-NPCs cultured in NSG (HS360), c) hESC-NPCs cultured in 
NDM (HS181). One group of rats with a laminectomy but without contusion injury (6 
animals/ group = sham rats) was injected with hESC-NPCs cultured in NDM 
(HS360). Animals were followed up to 12 weeks after injury and testing of hind limb 
motor function was performed one day before injury and 1, 3, 6, 10, and 12 weeks 
after injury. Hind limb function was assessed using the Basso, Beattie, and Bresnahan 
(BBB) motor performance scale, with 21 as the score for normal hind limb function, 
and 0 for complete paralysis. An experienced investigator blinded to the experimental 
design performed functional testing. After the motor assessment at 12 weeks, the rats 
were sacrificed, and perfusion-fixed with 400 ml of 4 % PFA in phosphate buffer, pH 
7.4. The dissected spinal cords were post-fixed in 4 % PFA for 90 min and thereafter 
rinsed and kept in 30 % sucrose until they were cut in 10 µm sections and processed 
for histological analysis.  
 
3.17 STATISTICAL ANALYSIS 
Statistical analysis was performed using SPSS Statistics. In paper II, Student’s t-test 
with Holm-Bonferroni’s correction for multiple comparisons was used, assuming 
random sampling from normally distributed data sets with equal variance. The 
statistical analysis of qPCR data was done using the Ct values (in log2 scale). In paper 
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III, to compare phenotype outcome after FACS and differentiation or propagation, two-
way repeated measures analysis of variance (ANOVA) followed by Dunnett’s post hoc 
test was used. Clonal expansion calculations were performed using Wolframalpha.com. 
The likelihood of a density of genes associated with certain gene ontology (GO) terms 
occurring by chance was calculated using Wolframalpha.com using the cumulative 
binomial distribution formula L(k;n,p) =  !!!! 𝑝!(1− 𝑝)!!! , where 𝑝 was set to be 
equal to the estimate 10 %, based on the frequency of the GO terms of interest 
annotated to 150 randomly chosen genes.  
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4 RESULTS AND DISCUSSION 
4.1 SIGNIFICANCE OF PLURIPOTENCY MARKER EXPRESSION IN 
NPCS  
Surprisingly, we found in paper I and II that hNPCs as well as human fetal tissue 
contain mRNA transcripts of genes strongly associated with the pluripotent phenotype. 
NANOG, OCT-4, SOX2, REX1, CRIPTO, DNMT3B and GDF3 mRNA was found in 
multiple cases. SOX2 is ubiquitously expressed by NPCs, hence included in our panel 
when comparing hESC-NPCs with fetal NPCs in paper I, but excluded from paper II. 
However, we could not confirm protein expression using antibodies that were able to 
demonstrate these proteins in hESCs. A possible explanation – and our initial 
hypothesis – for the existence of pluripotency-associated markers at the mRNA level in 
non-pluripotent hscNPCs is that the markers distinguish a subpopulation of cells in the 
heterogeneous hscNPC cultures forming the true stem cell population, the NSCs, 
should the expression be of significance to the phenotype of the cells, and limited to 
that population. As described in paper II, we have found no evidence for this, and 
although the phenotype of the NPCs expressing pluripotency-associated markers can be 
studied more extensively, for example by transcriptome analysis, the available data do 
not suggest that they have a specific phenotype. The question if these cells are or could 
become tumorigenic after transplantation should be thoroughly investigated before they 
are applied clinically, but among the large number of studies on human fetal CNS 
transplants to animal models, we are not aware of any reports of tumor formation after 
transplantation of human NPCs either to SCID mouse testis or to the injured spinal 
cord. Expression in an individual cell of one or a couple of transcription factors 
associated with a complex and tightly regulated phenotype such as pluripotency is most 
likely not enough to elicit expression of the complete proteome necessary for 
maintaining the phenotype (Toyooka et al., 2008).  
 
One single report of aberrant growth after clinical transplantation of fetal cells has 
surfaced (Amariglio et al., 2009). Beginning in 2001, a boy with the disease ataxia 
telangiectasia repeatedly received transplants of fetal cells, the origin of which is not 
entirely clear but seems to have been fetal tissue dissociated and transplanted 
immediately after abortion. Five years later, a tumor diagnosed as glioneural neoplasm 
was removed from his spinal cord. The tumor was found to consist of cells from at least 
two donors, but no host cells. The boy also presented with a slow-growing abnormal 
mass in the brain, which was not removed at the time. The spinal cord tumor cells 
appeared well-differentiated, also grew slowly and were multiclonal, which suggests 
that both tumors were relatively benign. Telangiectasia is associated with an increased 
cancer risk and it is possible that out-of-control donor cells could have escaped the 
boy’s immune system, which was weakened by the disease (Miyagi et al., 1995). The 
case may be drastically un-representative of likely future transplantation settings, both 
regarding graft origin and diagnosis, but nevertheless, the case provides the first proof 
that transplantation of fetal neural cells carries a risk of tumor formation.  
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Our results in paper II demonstrate that expression of pluripotency-associated TFs 
occurs in all or most fetal NPCs, but is concentrated to a small sub-population at any 
given moment. No particular phenotype could be ascribed to cells in that sub-
population; sphere formation characteristics as well as proliferation and cell death rates 
were similar to non-expressing cells. Is anomalous expression of pluripotency-
associated TFs the result of promoter-activated transcription or are they products of 
random transcriptional bursts, or both? We used lentiviral reporters driven by 
promoters for NANOG, REX1 and OCT-4, which have previously been shown to 
correctly mimic endogenous expression of TFs (Rodda et al., 2005). Importantly 
though, reporter genes using fluorescent proteins do not reproduce translation of the 
endogenous gene. Rather, GFP reporter expression and fluorescence intensity is 
directly proportional to GFP mRNA in eukaryotic cells (Soboleski et al., 2005). We 
confirmed, using qPCR after FACS selection of reporter-positive cells, that expression 
was two orders of magnitude higher in reporter-positive cells. Lentiviruses are 
incorporated semi-randomly into the genome (Schambach et al., 2013), implying that 
the position of integration can affect the probability of transcription, which is not 
evenly distributed in the mammalian genome (Chakalova and Fraser, 2010). The 
precise genomic positions of lentiviral incorporation can be determined, but with 
substantial effort. This was not done in our studies. Promoters are also known to leak, 
described as having one state with highly efficient transcription and one inactive state 
with very lowly efficient transcription (Huang et al., 2015). One conclusion that can be 
drawn in this particular case is that reporter-expression correctly mimics the behavior 
of transcription for a gene, but does not necessarily reflect concentration of the 
endogenous transcript. In other words, both random and specific transcription is 
reflected. Leaky promoters could be biologically relevant to sense the environment and 
activate transcription programs, while a completely static system remains static. The 
multitude of TFs required to elicit pluripotency may reflect that pluripotency is a 
“protected cell state”, well guarded by the cell. As pluripotent cells differentiate, 
chromatin rearrangements and other features block transcription of pluripotency-
associated mRNA, and the likelihood of the correct combination of mRNA species 
being transcribed by stochastic events is in that case low enough to avoid unwanted de-
differentiation. 
 
There are reports on results contradictory to ours. Ilieva and Dufva reported in 2013 
that OCT-4-and SOX2-mRNA positive cells were organized in the center of 
neurospheres derived from human fetal embryonic mesencephalon (Ilieva and Dufva, 
2013), suggesting that expression of pluripotency-associated mRNA species is 
accompanied with stem cell features in those cells. 
 
Either way, in future clinical applications, close monitoring of transplanted cells is 
required. For instance, positron emission tomography can be used non-invasively to 
monitor transplanted cells (Haralampieva et al., 2016). If aberrant growth is seen, 
various steps can be taken to eliminate the threat. For that purpose, systems to 
  34 
selectively induce apoptosis of transplanted cells have been conceived, using “suicide 
genes” (Di Stasi et al., 2011).  
   
 
4.2 CORRELATION BETWEEN mRNA AND PROTEIN 
The phenotypic identity of a cell is arguably best described by its proteome, i.e. the 
whole protein content at any given moment, but the transcriptome, i.e. the RNA 
content, is much easier to analyze. The protein concentration generally co-varies with 
the mRNA concentration in a cell, but the relationship is not absolute; about 40 % of 
the variation in the concentration of a typical protein species can be explained by 
knowing the concentration of the corresponding mRNA (Vogel and Marcotte, 2012). 
The poor correlation between mRNA and protein quantity is due to a number of 
characteristics that differ between mRNA and protein processing, and the fact that there 
seems to be no correlation between the processing of an mRNA species and the 
processing of its protein product. For instance: mean mRNA half-life is 5 hours in 
mammalian cells, and the range is narrow. Mean protein half-life is 46 hours with large 
variation. Furthermore, mRNA is produced at a rather slow rate, about 2 mRNA 
molecules per cell per hour, while hundreds of protein molecules can be produced per 
mRNA per hour, resulting in an estimated average mRNA:protein ratio of 1:2,800 
(Schwanhausser et al., 2011). 
 
In paper I and II, we demonstrated that mRNA, but not protein, of pluripotency-
associated species is present in non-pluripotent cells. How can the presence of mRNA 
but absence of detectable concentrations of protein be explained? There is a multitude 
of mechanisms regulating translation from mRNA to protein, such as microRNA and 
repressor proteins binding to mRNAs, inhibiting translation or mediating degradation 
of transcripts. Mechanisms modulating initiation of translation depend on secondary 
structure of mRNA, ribosome recruitment proteins and phosphorylation status of the 
species involved. In the specific case of pluripotency, there is a requirement of co-
expression of core transcription factors to elicit the phenotype (Wang et al., 2006). 
Likely, activation of translation is dependent on presence of multiple mRNA species; a 
feature that would ensure that developmental direction is maintained towards 
differentiation once cells down-regulate the pluripotent machinery and leave the 
pluripotent state (see section 1.2.2). When analyzed with virally transduced fluorescent 
reporters under the expression of promoters for OCT-4, NANOG and REX1, no co-
transcription of REX1/NANOG or OCT-4/NANOG was detected in the fetal NPCs 
studied in paper II. 
 
Piao et al. reported in 2006 that about 0.5 % of hscNPCs were immunoreactive for the 
markers Tra-1-60, Tra-1-81 and SSEA4 when analyzed with flow cytometry. During 
the work on paper I and II, using more rigid flow cytometry settings and other isotype 
control antibodies, we were unable to confirm those findings. Furthermore, no 
immunoreactivity to CD386 or OCT-4 could be demonstrated. Immunocytochemistry 
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experiments with antibodies against REX1 and NANOG also failed to detect protein in 
hscNPCs (see figure 11). 
  
 
 
 
Figure 11. Immunocytochemical 
analysis of NANOG in fetal 
hscNPCs, naïve hESCs and 
spontaneously differentiated 
hESCs (12d). hscNPCs do not 
stain for the NANOG antibody, 
whereas naïve hESCs are strongly 
stained, and spontaneous 
differentiation of hESCs for 12 
days generates weakly stained 
cells. 5,724 fetal cells were 
imaged, none of which showed 
detectable NANOG-
immunoreactivity. Nuclear staining 
(Hoechst, blue) and NANOG 
(magenta). Scale bar 10 µM. Image 
credit: John Schell. 
 
 
A more trivial explanation to the lack of protein, that of course should be addressed, is 
experimental failure. We cannot with absolute certainty claim that proteins of 
pluripotency-associated genes are absent from fetal NPCs, due to the possibility of 
failed immunochemistry experiments. The detection of immunoreactivity on hESCs in 
control experiments makes inability to detect protein less likely, but we have no 
information on lower detection limit.  
 
Two main types of experimental failure are further addressed below: Failure to exclude 
false positive RT-PCR results (representing a type I error); and failure to detect protein, 
although present (representing a type II error).  
 
4.2.1 Validation of RT-PCR Data 
RT-PCR is a sensitive method and proper negative controls are needed to minimize the 
risk of false positive results, which is ever present. We constructed primers to 
selectively bind mRNA by choosing primer positions traversing exon-exon boundaries, 
and to distinguish between genomic DNA and cDNA based on product length by 
placing primers in different exons, and evaluated primer specificity in silico as well as 
experimentally. Temperature-optimized RT-PCR experiments yielded single products 
with the expected size, evaluated by gel electrophoresis, and the products were 
Nanog/Hoechst Nanog
hscNPCs
hESCs
Differentiated
hESCs
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sequenced using the Sanger method, which confirmed that the products originated from 
mRNA. We can therefore conclude with a high level of certainty that mRNA was 
present. It should be noted, though, that detection of pluripotency-associated mRNA 
can be affected by the presence of mRNA transcripts of pseudogenes, particularly 
OCT-4 (Liedtke et al., 2007; Poursani et al., 2016).  
 
4.2.2 Validation of Protein Data 
Cyclic methods analyzing mRNA content are more sensitive than immunochemical 
methods to detect protein. Chances are that proteins are present but below detection 
level. The use of proper immunochemical controls confirms the specificity and 
sensitivity of the antibody, but the absolute absence of protein cannot be proved. 
Although the principle of linearity of protein sequence is similar to that of DNA and 
RNA, the central dogma of molecular biology states that no flow of information can go 
from protein to RNA or DNA, which probably prevents the possibility to develop 
cyclic methods for protein analysis. The alternatives to antibody-based techniques 
available today for unbiased detection of low levels of proteins rely on separation 
chromatography and mass spectrometry (Lesur and Domon, 2015).   
 
4.3 PLURIPOTENCY AND NEURAL PROGENITORS 
Arguably, the most important finding in paper I is that standard teratoma tests can fail 
to detect pluripotent cells, that give rise to teratomas in other transplantation settings. 
This was the obvious but slightly surprising conclusion of the fact that we repeatedly 
found tumor growth in the spinal cords of rats transplanted with NPCs derived from 
hESCs, in spite of the negative result from so called teratoma tests. In paper I and II, we 
also reported that the expression of pluripotency-associated mRNA species, either 
measured qualitatively or quantitatively, is not predictive of the potency state of human 
cells.  
 
A number of tests for validating pluripotency have been developed. The reasons for 
evaluating pluripotency of cells vary depending on the scientific question at hand. 
Many pluripotency tests are designed to confirm that the cells of interest (iPSCs, ESCs) 
are in fact pluripotent, and the tests’ validity therefore depend on their specificity. Tests 
to ascertain that no pluripotent cells remain prior to clinical transplantation require high 
sensitivity to be able to pick up all cells that could give rise to unwanted progeny in 
vivo. 
 
The methods for evaluating pluripotency include production of germ line competent 
chimeric organisms, tetraploid complementation, teratoma formation, embryoid body 
formation, and in vitro assays such as analysis of pluripotent-specific protein or mRNA 
marker expression, analysis of epigenetic state and morphological analyses (De Los 
Angeles et al., 2015; Smith et al., 2009). The tests mentioned above are listed in order 
of diminishing stringency regarding the ability to identify truly pluripotent cells. All 
methods have their advantages and drawbacks further discussed below (Smith et al., 
2009; Buta et al., 2013).  
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4.3.1 Tetraploid Complementation 
The most compelling evidence that a cell is pluripotent is if it can generate an entire 
healthy, fertile animal. When applying an electrical current to an embryo at the 2-cell 
stage, the cells fuse and a single tetraploid cell is formed, containing four copies of each 
chromosome instead of the normal two. That cell cannot give rise to a viable individual. 
However, it can give rise to the trophoblast, which later develops into the extra-
embryonic tissue, the placenta and the umbilical cord. By combining the tetraploid cell 
with pluripotent cell candidates and implanting into a surrogate uterus, a viable embryo 
can develop. The extra-embryonic tissue will develop exclusively from the tetraploid 
cells; the fetus will develop from the pluripotent cells. Although arguably being the 
most stringent pluripotency test, tetraploid complementation is ethically and practically 
not feasible for human cells. 
 
4.3.2 Chimaera with Germline Transmission 
In chimaera formation, presumed pluripotent cells are injected into an embryo, which 
generates a chimeric organism, consisting of a mixture cells from the original embryo 
as well as from the injected cells. The chimaera is then allowed to mature and give 
offspring. If successful germline transmission of the injected cells is accomplished, i.e. 
if some offspring of the chimaera carries genetic material only from the injected cells, 
the cells were pluripotent. Lately, interspecies chimaeras have been created, raising 
hope that entire human organs intended for transplantation could be grown from 
autologous stem cells in pigs, for example (Wu et al., 2016). For the purpose of the 
evaluation of pluripotency, creation of a chimeric organism will however remain 
restricted to non-human species due to the low contribution of foreign species stem 
cells in an interspecies chimaera and hence low sensitivity of chimaera formation as a 
test of pluripotency. 
 
4.3.3 Teratoma Formation Analysis 
Teratomas are spatially restricted, most often benign, tumors consisting of tissue or 
organ components not normally found in the organ in which they arise. The name 
teratoma stems from the Greek word ‘teras’ – monster, and the suffix –oma, denoting a 
tumor or neoplasm, because its constituents can resemble normal tissue, and have been 
known to include teeth, hair and even more complex organs. When evaluating cells for 
pluripotency by teratoma formation transplantation assay, the cells are usually injected 
into well-defined sites of immunocompromised (SCID) mice. Most commonly, cells 
are put under the skin (sub-cutaneously), directly in the muscle tissue (intra-
muscularly), under the kidney capsule or in the testis capsule. The major reasons for 
choosing the testis capsule are that the testis is easily accessible, both for 
transplantation and for evaluation of the tumor by palpation, and that the testis capsule 
provides a compartment in which the transplanted cells most often will stay and 
differentiate (Gertow et al., 2007). The resulting teratoma is cut out and processed for 
histochemistry. Naturally occurring teratomas can consist of cells deriving from one, 
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two or all three germ layers, endoderm, mesoderm and ectoderm. A teratoma from a 
homogeneous solution or body of pluripotent cells should consist of cells from all three 
germ layers, and to confirm this, antibodies labeling mesoderm-, endoderm- and 
ectoderm-specific markers are employed together with antibodies specifically labeling 
cells of the species from which the cells under investigation originated. Alternatively, 
the injected cells have been pre-labeled with stably expressed reporter genes. 
Haematoxylin-eosin staining is employed to facilitate microscope evaluation with 
normal, transmitted, light. The haematoxylin is positively charged and binds to 
negatively charged substances, primarily DNA and RNA, thereby staining the nuclei 
blue; eosin, on the other hand, is negatively charged, and binds to positively charged 
amino acid residues such as arginine and lysine, thereby staining proteins red. The local 
protein concentration determines the intensity of the staining and the color depth, which 
means that protein-rich structures, like muscle fibers, turn dark red, while structures 
with lower protein content, like mitochondria, turn palely pink. Structures high in fat, 
such as membranes and myelin, neither bind haematoxylin nor eosin. 
 
Teratoma formation assays are laborious, time consuming, ethically disputable, 
expensive and, as we and others have shown, subject to type II errors (Sundberg et al., 
2011; Zhang et al., 2008; Dressel et al., 2008; Hentze et al., 2009b) but nevertheless 
standard procedure in the scientific community for the evaluation of pluripotency in 
vivo. Several groups have used dilution strategies to evaluate the detection limit of 
pluripotent cells in teratoma formation assays. Non-pluripotent cells grafts have been 
spiked with pluripotent cells in low numbers and the rate and frequency of teratoma 
formation has been evaluated in various compartments in different animal species and 
strains. The most important factors increasing the sensitivity of the assays were low 
immunocompetence of the receiving animal and species similarity between donor and 
recipient. Other factors influencing the outcome were target compartment, graft 
embedding in Matrigel® and origin of the pluripotent graft. But, importantly, as few as 
two pluripotent cells could generate a teratoma after transplantation in the most 
sensitive model, highlighting the importance of rigorous methods to make sure 
pluripotent cells are excluded from clinical grafts (FDA, 2008; Hentze et al., 2009a; 
Lawrenz et al., 2004). The teratoma tests in paper I, were hESC-NPCs either in single-
cell suspension or as neurospheres were injected subcutaneously and into the testes of 
mice with severe combined immunodeficiency (SCID), did not give rise to any 
identifiable teratomas. However, cells from the same cultures produced rapidly 
growing teratomas in the lesioned spinal cords of immunodeficient rats. Species 
differences as well as differences between target compartments – immunological or 
other – likely explain the different outcomes. The fact that the spinal cord was injured, 
a situation associated with long-term inflammation, may have increased the propensity 
for local tumor development. We therefore suggest that safety testing of cell therapy 
should always be performed in the intended target regions.  
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4.3.4 Embryoid Body Formation and Directed Differentiation 
Correspondingly to in vivo teratoma formation, embryoid body (EB) formation can be 
used to retrospectively identify pluripotent cells in vitro. But, in contrast to in vivo 
teratoma formation, EB formation is, due to low sensitivity, primarily not an assay for 
analysis of small contribution of remaining pluripotent cells. EBs, irregular lumps 
consisting of cells from all three germ layers, form when pluripotent cells are 
differentiated under certain conditions in vitro. The process recapitulates many aspects 
of cell differentiation in early development (Kurosawa, 2007). Other models of 
spontaneous or directed in vitro differentiation can also be used to specifically 
determine the potential of cells to form different progeny such as neural (Chambers et 
al., 2009) and cardiac (Hoebaus et al., 2013) stem/progenitor cells. 
 
4.3.5 Protein Expression Analysis 
As mentioned in the background (section 1.2.3), a number of proteins have been 
associated with the pluripotent state, but claims that any single protein (most notably 
NANOG) is both selective and specific for pluripotent cells, have been refuted (Chan et 
al., 2009; Kalmar et al., 2009). The work by Sundberg et al. preceding paper I 
identified the transmembrane glycoprotein CD326 (EpCam) as differentially expressed 
between hESCs and their neural progeny (Sundberg et al., 2009). It is not, however, 
specific to pluripotent cells, but expressed in a variety of human epithelial tissues. 
Thomson et al. described the first hESC cultures in 1998 and established that they 
expressed cell surface markers previously known to characterize primate ESCs, 
including TRA-1-60, TRA-1-81, SSEA3, SSEA4 and alkaline phosphatase (Thomson 
et al., 1998). Although non-pluripotent cell types express the cell surface markers listed 
by Thomson et al. in various combinations, the complete cell surface marker profile 
listed in that seminal paper has been a model for hESC research ever since, and, to my 
knowledge, no non-pluripotent cell has been shown to express the whole profile. This 
may, of course, be for technical reasons. Importantly though, there have been reports of 
human pluripotent cells lacking expression of markers on that list, leading to the 
conclusion that any comprehensive list of markers is not selective for hESCs (Brimble 
et al., 2007). Likely, co-detection of many or all of the factors involved in maintaining 
the pluripotent state is necessary to absolutely unambiguously claim that a cell is 
pluripotent, but more research is needed before any protein data-based claim that cells 
are not pluripotent is possible. Multiplex proteomic assays using mass spectrometry 
constitute a promising means to that end (Baud et al., 2017). Alongside antibody-based 
techniques to detect and quantify proteins, spectrometry-based techniques are rapidly 
evolving. 
 
In paper I, small populations (1-5 %) of the hESC-NPCs were immunoreactive for the 
pluripotency-associated proteins SSEA-4, OCT-4 and CD386, while fetal NPCs were 
not, indicating that protein data is more predictive of teratogenic potential than mRNA 
data.  
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4.3.6 mRNA Expression Analysis 
Differentiation of pluripotent cells is routinely monitored over time by analyzing 
changes in the mRNA pool. In neural progenitor populations derived from pluripotent 
cells in vitro described in paper I, OCT-4, NANOG and DNMT3B mRNA 
concentrations declined to undetectable levels already within 2 weeks of neural 
induction, while the same mRNA species remained at detectable levels in fetal cells, 
that did not create teratomas is any compartment tested. Although not statistically 
confirmed, a slow down-regulation of DNMT3B mRNA could be discerned in fetal 
cells over 12 weeks, but OCT-4 and NANOG mRNA levels were oscillating without 
following any salient pattern over the 5 time points investigated during 12 weeks. In 
paper II, using retroviral reporters, we found that expression of NANOG, OCT-4 and 
REX1 mRNA was most prominent in distinct, small subsets of hscNPCs at any given 
time point, and that those populations were reestablished after depletion sorting, 
indicating that fluctuating expression is inherent to all or most hscNPCs in vitro. 
Multiplex, single cell qPCR and whole transcriptome analysis of single cells with other 
cyclic methods have become more accessible, and data from such experiments will 
most certainly add important information in the future. 
 
4.3.7 Analysis of Epigenetic State 
The epigenetic states of pluripotent cells, as well as the epigenetic changes associated 
with differentiation have been studied (Zhao et al., 2007), and theoretically, it should be 
possible to determine the potency of a cell solely based on its genetic code and 
epigenetic configuration, but the biochemical processes involved in transcription and 
translation are far too complicated for any kind of reliable prediction to be possible in 
the foreseeable future. 
 
4.3.8 Morphology Analysis 
Distinguishing between a pluripotent and a differentiated cell based on morphology 
alone is not possible, but certain distinct morphological traits characterize pluripotent 
stem cells: Regardless of whether pluripotent stem cells are cultured on matrix substrate 
or feeder cells, they usually form flat and compact colonies with sharp edges. 
Individual pluripotent stem cells are typically round and have a large nucleus compared 
to the soma. Significant experience is required to be able to validate the quality of stem 
cell cultures based on morphology (Holm, 2012). 
 
4.4 ANALYSIS OF SPHERE FORMATION  
Culturing cells as neurospheres entails some difficulties regarding for instance 
monitoring the morphology of living cells or estimating the cell number in a culture 
without dissociating the spheres. The neurosphere culture method has been used for 
more than 20 years and for many types of cells, including cancer cells, mesenchymal 
stromal cells, pancreatic cells etc., to propagate cells without substrate. It is also used as 
a method of analysis measuring the cells’ ability to form presumably clonal spheres, 
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which would indicate ‘stem-ness’. The notion that all spheres originate from a single 
sphere-forming cell has however been refuted (Pastrana et al., 2011; Singec et al., 
2006). We have also seen that sphere fusion is a common event and have substantial (or 
at least circumstantial) evidence that cell-cell contact may be necessary for proliferation 
of hscNPCs in a non-adherent setting. When individual hscNPCs are put in one 96-well 
each with conditioned medium, no spheres are formed.  
 
If the sphere-forming cells were the true stem cells, it would indicate that only a certain 
subset of cells have the intrinsic ability to form spheres. In an attempt to identify that 
putative subset we FACS sorted cells with specific traits in different wells and analyzed 
their sphere-forming ability with image analysis. Neurospheres are somewhat 
transparent and best viewed with phase contrast microscopy, a technique which 
converts phase shifts in light passing through cells, that have different refractive index 
than the growth medium, to brightness changes in the image. In order to make an 
automated, un-biased analysis of a large number of images, we created a script that 
could be run in the freeware ImageJ. There are several commercially and freely 
available software and hardware solutions that all have emerged since we initiated this 
project: Celígo 3D Tumor Spheroid Analysis from Nexelcom; VisionGauge from 
Visionx; Cell Profiler and ImageJ macros. For an overview, see (Choudhry, 2016). 
 
A more thorough analysis of sphere forming is feasible using time-lapse video 
monitoring of single cells in the process of sphere forming, possibly in gelatinous 
medium to reduce the motility of cells. Freely floating hNPCs in vitro exhibit not only 
Brownian motion, but also motion probably associated with elongation of processes 
and contact inhibition/attraction. 3D Matrigel matrices have previously been used for 
the purpose of monitoring proliferating and/or differentiating cell aggregates in vitro, 
but in this case, the growth factor constituents of regular Matrigel, as well as the 
laminins (still present in growth factor-reduced Matrigel) would most likely affect 
sphere formation and proliferation. 
 
4.5 CHOOSING TYPE OF CELL FOR SCI TRANSPLANTATION 
Identifying the optimal cell mixture for SCI transplantation necessarily involves the 
identification of the mechanism(s) primarily responsible for functional recovery. We 
have previously shown that transplantation of human NPCs in the form of neurospheres 
improves functional outcome in several rat SCI models, and is associated with a 
survival of donor cells, which surpasses that of transplanted dissociated cells. The 
mechanisms by which the transplanted cells exert their effect are probably several but 
rescue of injured host neurons is an important factor. We have also shown that SCI rats 
transplanted with cells derived from human fetal spinal cord improve to a higher degree 
than rats transplanted with forebrain-derived human fetal cells (Emgard et al., 2014). 
Speculation can be made that this is the result of regional-specific cell characteristics – 
such as cell surface antigen expression or factors excreted – that remains during cell 
culture (Piao et al., 2006). Others have shown functional recovery after transplantation 
of fetal forebrain-derived spheres as well as spinal cord-derived spheres (Watanabe et 
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al., 2004). The initial rationale for paper III was to use cell surface molecules to select 
for certain phenotypes (see section 1.2.4), which would make it possible to transplant 
purified populations of cells and elucidate which mechanisms are responsible for 
functional recovery. Isolation, in vitro proliferation and subsequent transplantation of 
lineage restricted NPCs would aid in determining the cell type, and thereby the 
mechanisms, responsible for the functional improvement of transplanted SCI rats. Also, 
since transplantation acutely or possibly subacutely seems preferred (Emgard et al., 
2014), cells intended for a prospective clinical application of neurospheres will most 
likely be cultured after sorting and banked in sufficient number for fast access upon 
request. Cells can be isolated by immunolabeling and subsequent cell sorting by 
fluorescence-activated cell sorting (FACS), immunopanning or magnetic-activated cell 
sorting (MACS). We decided to use FACS, which has the advantage of simultaneous 
analysis and sorting of the cells, although the yield can be substantially lower, and there 
is a risk of exposing the cells to shear forces and pressure transients in the FACS 
apparatus. As described in paper IV, pressure changes in the Biogrid device far 
surpassing those induced by the FACS have no obvious effect on cell survival or 
phenotype outcome. Furthermore, confusing preliminary data generated with 
immunopanning led to a decision to avoid that technique. In hindsight, the confusing 
data may have represented the main finding of paper III, that NPCs interconvert in 
vitro, but we had no idea at the time. 
 
4.6 PHENOTYPE INTERCONVERSION 
Surprisingly, culture homogeneity after FACS sorting for the cell surface antigens 
CD15, CD133, CD24, A2B5 or PSA-NCAM could not be maintained over time in 
culture with regard to 1) expression of the antigen for which the cells were sorted, 2) 
the transcriptome and 3) phenotype outcome in various in vitro assays presented in 
paper III. We believe that the observations reflect consequences of phenotype 
interconversion. Phenotype interconversion has previously been reported to occur in 
non-neural cells, e.g. hematopoietic progenitors (Chang et al., 2008), breast cancer cell 
lines (Gupta et al., 2011) and primary muscle cells (Stockholm et al., 2010). Chang et 
al. showed in 2008 that phenotype cell-to-cell variability within a stem cell culture is a 
manifestation of transcriptome-wide expression noise, which controls lineage choice 
but does not generate irreversibly committed precursors. The slow relaxation (requiring 
more than 12 cell doublings) of FACS sorted progenitors with distinct transcriptional 
profiles to the parental distribution of the marker for which the cells were sorted 
suggested the existence of multiple stable cell states – attractor states – along the way 
(Chang et al., 2008). Similarly, Gupta et al. described in 2011 the dynamics of 
interconversion of breast cancer cells between differentiated states and a stem cell state 
using a Markov model, with probabilities of interconversion between all states (Gupta 
et al., 2011). We have not demonstrated direct conversion between states far out on 
either side of the neuronal-glial fate spectrum (i.e. A2B5-/PSA-NCAM+ neuronal 
precursors and A2B5+/PSA-NCAM- glial precursors), but rather propose that 
interconversion of NPCs goes via an un-biased cell state. It has previously been shown 
that the original cell fate of mouse neural precursor cells is lost in neurosphere cultures 
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(Machon et al., 2005) and that rat oligodendrocyte precursors can revert back to a 
multipotent stage in the presence of bFGF (Kondo and Raff, 2000), which may, in the 
light of our findings, be effects of phenotype interconversion. In contrast to the finding 
by Ravin and co-workers that uni-potent cells in rat cerebral cultures are reset to a tri-
potent stage at passage (Ravin et al., 2008), fetal hNPCs in our system lost their antigen 
profile and presumed uni- or bi-potency also without passaging, which may reflect 
differences between species or culture conditions. We evaluated the possible 
contribution to the observed results of two confounding factors: low sorting purity and 
clonal expansion. Increasing the stringency of the FACS sorting by only collecting a 
small proportion of NPCs with the highest immunoreactivity, to compare them with 
NPCs with no immunoreactivity did not change the outcome. Likewise, mathematical 
models of culture behavior into which small populations with deviating proliferative 
features were used including parameters based on experimental observations (see figure 
14). These models produced outcomes that did not at all resemble experimental 
observations. Furthermore, no NPC cultures investigated have presented with 
detectable changes in karyotype. Clonal expansion in vitro is associated with genetic 
alterations and chromosomal aberrations of rapidly growing cells.  
             
Figure 13. Graph illustrating the results of mathematical modelling of clonal expansion using the Deasy 
equation (Deasy et al., 2003), which are inconsistent with experimental observations. Model population 1 
represents a 1 % rapidly growing contaminating subpopulation. Population 2 represents the 99 % cells in 
the population with one 10th the proliferation rate of pop. 1. The resulting fold expansion in the model is 
illustrated with the dotted black line. A segmented grey line represents the in vitro proliferation of 
hscNPCs observed experimentally. 
 
To further examine the possible involvement of clonal expansion by a small 
subpopulation, we sorted CTV-stained cells based on both CD15- and CD133-
immunoreactivity, cultured them in NSG medium, and analyzed CTV fluorescence 
intensity and CD15- and CD133-immunoreactivity 10 and 33 days later. Initially, 
CD15+/CD133+ cells proliferated faster than CD15-/CD133- cells, but the effect of the 
sorting waned after about one week. As expected, CTV stain intensity measured with 
flow cytometry was higher in the population that was CD133-/CD15- at sorting than in 
their CD133+/CD15+ counterparts at 10 and 33 days after sorting, confirming that 
CD133-/CD15- cells initially proliferated slower than CD15+/CD133+ cells. However, 
the proportions of CD15- and CD133-immunoreactive cells had been reset, partially 
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with respect to CD15 at 10 days, completely with respect to CD133 at both time points 
and CD15 at 33 days, and CTV fluorescence intensity was not correlated to CD133 or 
CD15 immunoreactivity at 10 or 33 days after sorting, indicating that interconversion 
took place in all populations to similar extent. Furthermore, there was no difference in 
the rate of CTV signal decline between the subpopulations between 10 and 33 days, 
presumably after interconversion had occurred, indicating that there was no 
subpopulation solely responsible for reconstituting the population via clonal expansion.  
 
It is also important to note that clonal expansion of a small subpopulation – although 
not consistent with any of our observations – would not contradict the concept of 
interconversion, since the proportions of cell expressing markers for which the cells 
had been sorted approached the same value as FACS flow-through control cells 
asymptotically, indicating a population attractor state for each marker in our culture 
system (see paper III, figure 1). Rapidly dividing cells falsely detected as negative in 
the FACS that would only give rise to clones of positive cells in a negative population 
would take over the culture and all cells would be positive, which was never the case. 
The reversed scenario would consist of cells falsely registered as positive giving rise to 
negative progeny in a positive population, rendering it negative, which also never 
occurred. Also, for NPCs sorted with respect to PSA-NCAM, A2B5 and CD24 
immunoreactivity, no differences in growth rate between positive and negative 
populations could be seen at any time point. As demonstrated in paper III, fig. 7b, fresh 
tissue from human CNS contains about 2-20 % CD133-immunoreactive cells, which 
rapidly acquire CD133 expression in vitro, initially from selective growth of CD133+ 
cells, and later also from interconversion (paper III, fig. 1, left panel).   
 
4.6.1 Phenotype Accompanies Re-setting of Surface Marker Profile  
CD15+ hscNPCs did not form a higher number of spheres than CD15- cells, but 
displayed a higher proliferation rate, which resulted in larger spheres (paper III, fig. 5). 
This was analyzed by un-biased, semi-automated image analysis as described in section 
3.8. The difference in proliferation rate was linked to CD15-immunoreactivity, which 
changed over time in culture. Similar results have been reported for the proposed stem 
cell marker β-1-integrin, the loss of which is accompanied by lower proliferation rate 
and higher mortality, but not loss of sphere forming capacity (Leone et al., 2005). 
CD15 expression in mouse cortical progenitor cells has been shown not to change with 
the cell cycle, indicating that it reflects proliferative potential rather than cell cycle 
stage (Capela and Temple, 2006). It has also been reported that serially sorted CD15+,- 
mouse NPCs do not form neurospheres (Kelly et al., 2009). hscNPCs in our system 
were able to form spheres after serial sorting (CD15-,- or CD15+,-), both with and 
without passaging in between. This may indicate a higher propensity of hscNPCs to 
interconvert. 
 
A2B5-/PSA-NCAM+ cells generated a higher proportion neuronal progeny than 
A2B5+/PSA-NCAM- cells, but were not committed to the neuronal fate. As PSA-
NCAM immunoreactivity was reset within weeks of continued culturing with mitogens 
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after cell sorting, differentiation fate bias was also lost. FACS sorting per se actually 
increased the ratio of GFAP:β-tubulin III-IR cells after subsequent differentiation, 
probably because neuronal progenitors are more sensitive to the FACS conditions, 
which include rapid pressure changes and comparatively long periods of both mitogen 
and cell-cell contact depravation. Other sorting methods, such as MACS or immuno-
panning, may be gentler for neuronal progenitors (discussed in section 4.5). PSA-
NCAM-IR neuronal progenitors have longer, thinner processes and smaller cell bodies 
than PSA-NCAM-negative hscNPCs, and co-localize with MAP2 and β-tubulin III 
immunoreactivity to some extent (see figure 14). When cells are dissociated, having 
long, thin processes may be disadvantageous for maintenance of membrane integrity 
and cell survival, which could explain the lower yield of neurons directly after sorting 
as well as the accumulation of glial progenitors over time in fetal NPC cultures (see 
section 1.2.6.3). We have not detected any difference in growth rate or Ki-67 
immunoreactivity related to PSA-NCAM immunoreactivity. Co-localization of Ki-67 
and PSA-NCAM staining in adherent hscNPCs is shown in figure 13. Ki-67 
immunoreactivity also largely co-localized with MAP2 immunoreactivity in hscNPC 
adherent cultures, but not with MAP2 immunoreactivity in NBM cultures after 12 days’ 
differentiation. 
 
 
 
Figure 14. Upper left: MAP2- (red) and PSA-NCAM-IR (green) adherent hscNPCs. Upper right: MAP2- 
(green) and Ki-67-IR (red) adherent hscNPCs. Lower left: PSA-NCAM- (green) and Ki-67-IR (red) 
adherent hscNPCs. Lower right: PSA-NCAM- (green) and Ki-67-immunoreactivity (red) does not co-
localize after 12d differentiation in NBM. Similar results were obtained using MAP2/Ki-67 staining of 
cells differentiated 12d in NBM (data not shown). 
 
Most hscNPCs differentiate into GFAP-immunoreactive cells after transplantation in 
vivo or serum-induced in vitro differentiation (Emgard et al., 2014) irrespective of 
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sorting. In our studies, the differences in proportion of GFAP-IR progeny between 
A2B5+ and A2B5- cells did not reach statistical significance (data not shown). 
Evaluation of their morphology revealed that not all GFAP-IR cells had typical 
astrocytic morphology, but the difference in proportions of GFAP-IR cells with typical 
astrocytic morphology did also not reach statistical significance (data not shown). 
Although the proportion of β-tubulin III IR progeny from A2B5+ cells after differentia-
tion in NBM was significantly lower than FT control cells (data not shown), 
transcriptome analysis revealed that there was no significant transcriptome profile 
associated with A2B5 immunoreactivity, indicating that A2B5 sorting is of little, if any, 
consequence for hscNPCs, especially if culturing afterwards is required. 
 
CD133 has been used to prospectively sort out neural stem cells from adult mouse 
subependymal zone (Beckervordersandforth et al., 2010), and it has been shown that 
human embryonic forebrain CD133+/SSEA-4+ and CD133+/CD15+ subfractions are 
enriched in neurosphere-initiating cells (Barraud et al., 2007). CD133 immuno-
reactivity correlates with cell DNA content and thus to cell cycle stage and has been 
shown to interconvert in human embryonic stem cells and various cancer cell lines 
(Jaksch et al., 2008). As described in paper III, while CD133- cells from freshly 
dissected human fetal spinal cord and subcortical forebrain did not form spheres, 
CD133- cells from already established hscNPCs cultures did, but much slower than 
CD133+ or FT control cells. There is a possibility that the CD133- population of 
hscNPCs was contaminated by CD133+ cells that have been enzymatically stripped of 
their surface expression of the CD133 molecule by the dissociation enzyme TrypLE 
Express, and therefore falsely registered by the FACS as CD133-. Freshly dissected 
human fetal spinal cord and subcortical forebrain, on the other hand, was routinely 
dissociated mechanically, without enzymes.  
 
4.6.2 Phenotype Interconversion Is Likely a Cell Intrinsic Feature 
In paper III, we tried two different approaches to investigate whether cell-cell 
interactions govern interconversion kinetics. First, we treated cells with the γ-secretase 
inhibitor L-685,458 without detecting any effect on interconversion. Second, we used 
GFP-expressing cells to be able to follow the behavior of PSA-NCAM+ cells in a 
mixed culture with PSA-NCAM- cells, and, similarly, A2B5+ cells in a mixed culture 
with A2B5- cells. The results indicated that there was no that mechanism sensing the 
proportions of cells expressing PSA-NCAM or A2B5. Also, PSA-NCAM IR cells are 
randomly distributed in adherent and neurosphere hscNPCs, contradictory to the 
hypotheses that either mitotic bias or lateral inhibition is responsible for resetting 
population frequencies. However, we have shown in paper II that adherent hscNPCs 
are highly motile and probably move around too fast for any conclusion to be drawn 
from a still image regarding population control mechanisms. We have not investigated 
the kinetics with which individual cells transform from, for example, a PSA-NCAM+ 
state to a PSA-NCAM- state. The fact that PSA-NCAM-IR cells are disproportionally 
slim and neuron-like combined with the relatively short time course of dramatic 
morphology changes of adherent hNPCs described in paper II 
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indicate that individual cell state transition kinetics may be of importance for 
understanding interconversion. On population level, we have shown that full 
interconversion occurs within 3 passages. Individual cells may flip between states 
much more rapidly, with certain probabilities to exist in any given state, and slower 
cellular events may primarily affect the probabilities, but not the cell state per se. Such 
events could probably be investigated using reporters and time-lapse imaging, as has 
been done for NOTCH1 (Shimojo et al., 2008) and NANOG (Kalmar et al., 2009).  
We nevertheless conclude that relaxation to a population attractor state is driven by 
mechanisms inherent to individual hNPCs. 
 
4.7 TRANSCRIPTOME ANALYSIS OF PHENOTYPE INTERCONVERSION 
In paper III, to determine if resetting of the cell phenotype occurs in parallel to surface 
antigen profile, transcriptional analysis was performed on acutely sorted hscNPCs as 
well as hscNPCs sorted and then cultured for 3 passages. The transcriptional profiles of 
cells sorted based on immunoreactivity for A2B5 and PSA-NCAM were surprisingly 
homogenous within biological replicates. Un-biased, automated clustering revealed 
larger differences between biological replicates than between sorted populations. 
Nevertheless, the differences in the transcriptome between sorted populations were 
missing three passages later, indicating that interconversion takes place on the 
transcriptome level as well as on the cell surface. 
 
Transcriptome analysis revealed 19 genes significantly upregulated in the A2B5-/PSA-
NCAM+ population, and an analysis of GO terms associated to those 19 genes 
suggested that the cells were biased towards a neuronal fate, which was confirmed by 
in vitro experimental data (see sections 3.2.2.2.3 and 4.6.1). Three passages later, when 
the A2B5-/PSA-NCAM+ population had interconverted with regard to cell surface 
profile as well as preferential differentiation bias, there was no memory of the sorting 
among the previously significantly up-regulated 19 genes as evaluated by ranking score 
(paper III, fig. 8 and table 3). Whether transcriptional events or cell surface expression 
mechanisms govern interconversion kinetics is a chicken-or-egg-type of question that 
cannot be answered by our present data, but we conclude that alterations in cell surface 
expression of A2B5 and PSA-NCAM is accompanied by transcriptome profile 
alterations. 
 
4.8 EPIGENETICS AND STOCHASTIC EXPRESSION  
In paper II, we showed that the proportion of cells expressing pluripotency-associated 
TFs decreased after differentiation. We have also seen that after 14 days of in vitro 
differentiation in NS-FBS, hsc-derived cells detached and died when NS-FBS medium 
was exchanged for NSG medium containing mitogens (data not shown) and could 
therefore no longer be investigated for interconversion, and may have irreversibly lost 
their NPC features. For each final cell fate, there seems to be a point of no return where 
cell fate decision is made irreversible (see figure 15). Epigenetic regulation of 
transcription and chromatin status probably affects the likelihood of stochastic 
expression for genes that are silenced as cells differentiate (Chalancon et al., 2012; 
  48 
Trott et al., 2012). To validate this hypothesis with regard to interconversion, we treated 
hscNPCs with valproic acid (VPA), a histone deacetylase inhibitor, whose actions lead 
to higher histone acetylation levels and thereby higher accessibility for transcription. 1 
mM VPA treatment of sorted cells did not significantly affect the kinetics of 
interconversion (data not shown). 
 
Just as epigenetics influence the probability of stochastic events, gene expression noise 
can direct epigenetic changes. Studies on the evolutionary advantages of using 
epigenetics to exploit stochastic expression revealed a trade-off between adaptation 
time and robustness of the acquired phenotype, favoring epigenetic changes in a rapidly 
changing environment, and genetic adaptation in slowly changing environments 
(Gomez-Schiavon, 2016). 
 
Although the in vitro conditions for propagating NPCs are well defined, one could 
argue that the environment is less rigid and contains fewer determining cues than the in 
vivo situation, which could further induce the mechanisms governing stochastic 
expression. The lack of proper developmental control in vitro can be illustrated by the 
fact that hscNPCs express combinations of transcription factors not found in vivo 
(unpublished data, Alekseenko et al.). Austin Smith has formulated a similar remark 
regarding pluripotency in vitro and in vivo:  
 
“Observations of fluctuating gene expression and phenotypic 
heterogeneity in vitro have fostered a conception of pluripotency as an 
intrinsically metastable and precarious state. However, in the embryo 
(…) the properties of pluripotent cells change in an orderly sequence.” 
(Smith, 2017) 
 
 
   
Figure 15. Schematic representations of the hierarchy of potency of cells along the neuroectodermal 
lineage in vitro. On the left: Hypothesis under which the studies in the present thesis were initiated. A 
pluripotent cell (plum) gives rise to a multipotent neural progenitor (blue), which gives rise to restricted 
progeny, glial (green) and neuronal (red), which in turn generates terminally differentiated cells. On the 
right: Model of hierarchical relationships that better fits experimental in vitro observations. Neural 
progenitor cells exist in different states, associated with varying probabilities of differentiation, but with 
maintained multipotency. Flipping between states – phenotype interconversion – involves alterations of 
the transcriptome. Dotted lines signify points of no return, which only allow passage from above.   
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4.9 ROAD TO CLINIC/PRODUCTION OF CELLS UNDER GMP  
Culturing and transplanting spheres has several advantages compared to single cells. 
First, there is no need for addition of exogenous ECMs to culture plates. Cells in 
neurospheres create their own microenvironment containing appropriate cell adhesion 
molecules and growth substrates, promoting growth and survival. Second, from 
published transplantation studies it can be concluded that cell survival after 
xenotransplantation of neurospheres surpasses that of single cells (see discussion in 
Emgård et al., 2009). The possible drawbacks of using neurospheres are at first glance 
threefold, two of which have to do with standardization rather than outcome. First, 
precise quantification of cell number is difficult, if not impossible. We have determined 
the equation describing the relation between sphere diameter and the number of hNPCs 
in individual spheres, based on counting the number of cells in a large number of 
spheres of different diameters. Second, using neurospheres adds a level of complexity 
to the transplantation situation. Which sphere size is optimal for transplantation? 
Choosing sphere size for transplantation depends on the delivery method and the status 
of the cord. Our preclinical data suggest that acute or possibly sub-acute transplantation 
is preferred (Emgard et al., 2014), which would in many occasions allow access to the 
cord during acute decompressing or stabilizing surgery. Open surgery at a later time 
point for the sole purpose of cell transplantation entails additional risks of infection, 
bleeding and other complications that are less likely to be accepted by the patients as 
well as the ethical review board. Secondary surgery was also a reason for significant 
dropout in the Pathway study conducted by StemCells Inc. In our setting of 
experimental SCI model transplantation, a Hamilton syringe with a pulled glass 
capillary is used for administration of spheres in open surgery, setting an upper limit to 
the sphere size at about 300 µM. Irrespective of the transplantation method and 
knowing that pulled glass capillaries will never be used for injections into patients, it is 
beneficial to be able to see the tissue to be transplanted to increase the chances that it 
ends up were it’s supposed to go, especially when transplanting to fluid-filled 
compartments such as posttraumatic syringomyelia cysts, which we currently are 
studying (but not as a part of this thesis). A 300-µm sphere is clearly visible to the 
naked eye. 
 
Sphere size is also related to the third drawback of a clinical use of neurospheres. There 
have been reports of increased cell death and differentiation in the middle of 
neurospheres derived from mouse brain cells and human glioma cells as sphere size 
increases, maybe because of limited diffusion of mitogens or other factors into the 
spheres (Azari et al., 2011; Rahman et al., 2015; Walker and Kempermann, 2014). We 
have not been able to confirm those observation using fetal NPCs, as apoptotic markers 
and markers for differentiated cells were not unevenly distributed in sectioned spheres 
(data not shown), and increased cell death was not seen in the center of hscNPC spheres 
as large as 1 mm across. Contradictory observations regarding the heterogenic 
distribution of proliferating cells in neurospheres highlight the need for thorough 
investigation of each neurosphere model system: rapidly proliferating progenitors have 
been reported to constitute the outer rim as terminally differentiated cells accumulated 
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in the middle of neurospheres derived from mouse dentate gyrus (Babu et al., 2011; 
Reynolds and Rietze, 2005), while neurospheres from human fetal mesencephalon 
displayed the opposite, as differentiation occurred primarily at the rim and 
undifferentiated cells remained in the center (Ilieva and Dufva, 2013).  
 
We have preliminary data indicating that cells grown as spheres behave slightly 
differently compared to adherent cells, especially with regard to dorso-ventral identity 
and nestin expression. Adherent NPCs – which are routinely cultured on laminin-111 – 
presented a more ventral identity than NPCs in neurospheres, as shown by the 
expression of positional transcription factors. Adherent NPCs also contained a higher 
proportion cells immunoreactive for the marker nestin, implying that adherent cultures 
are more homogeneously immature than neurospheres (unpublished data, Alekseenko 
et al.), which has also been suggested by others (Conti and Cattaneo, 2005). 
Nevertheless, the features of the two culture systems seem reversible, as spheres of 
hscNPCs and hfbrNPCs can be made adherent and vice versa (see section 3.2.2.1). 
 
Thus, depending on the actual situation, there may be strong reasons to choose 
neurospheres for clinical transplantations. In these applications, culture conditions 
under GMP will likely require mechanical instead of enzymatic dissociation, to 
eliminate the risk of contaminating the transplanted tissue with proteolytic enzymes. In 
paper IV we describe the Biogrid device that reliably and with high reproducibility 
allows dissociation of neurospheres and hESC aggregates in solution in automated 
systems. It is reasonable to believe that cell aggregates of other origins, such as 
hepatocytes, MSCs or even plant cells could be dissociated as well. We showed that the 
pressure transients at Biogrid passage do not induce cell death of hNPCs, and that the 
proliferation achieved using Biogrid – ≈100-fold during 10-13 weeks – is similar to 
enzymatically passaged hNPC cultures and sufficient for efficient in vitro expansion of 
hNPC cultures. Proliferation after enzymatic dissociation was more variable. The 
proportions of differentiated progeny within neurospheres were not affected by passage 
method.  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
Clinical transplantation of progenitor cells to the human CNS requires in-depth 
investigation of tumorigenic potential of grafted cells, not only by standard SCID 
mouse teratoma tests, but also by long-term follow up of transplantation to the intended 
target compartments of other model animals. Furthermore, we have corroborated the 
findings that mRNA data is less predictive of pluripotency than protein data.  
 
We have shown that phenotype interconversion is a common feature of neural 
stem/progenitor cells derived from human fetuses in vitro, a feature that also affects 
pluripotency gene expression. Whether this is a phenomenon attributable to the 
artificial in vitro milieu and of limited interest to the in vivo situation should be more 
thoroughly investigated. Specified progenitors certainly exist in vivo, but our results 
show that it is not possible to propagate them with retained specificity in vitro. 
Applications such as clinical transplantation of stem cells will most likely depend on in 
vitro expansion of cells to secure the accessibility of material, and phenotype 
interconversion should be taken into account, especially when culturing selected 
subpopulations of heterogeneous cultures. To selectively culture specified progenitors 
of hscNPCs may be possible by using other culturing methods than the ones used in 
this thesis, including other media formulations and growth conditions. In NSG medium, 
cell surface expression, or even transcriptional profile, of a cell population or individual 
cell only provides a snapshot of the population’s or individual cell’s propensity to 
differentiate. Therefore, the hierarchical model of phenotype specification for these 
cells must be questioned. In the absence of truly determining cues for entering terminal 
differentiation, hscNPCs seem to remain within the unspecified realm, exploring it.  
 
Finally, production of cells for clinical transplantation will require new, standardized 
culturing techniques devoid of animal-derived content and factors such as proteolytic 
enzymes that may have unforeseen effects on the cells to be transplanted or the 
recipient. The Biogrid device can be used in automated systems for dissociation of cell 
aggregates intended for therapeutic use, enabling large-scale culturing of hNPCs as 
well as other cells. 
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